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Abstract 
 
  Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent issue in 
the modern world, predisposing patients to serious pathology such as cirrhosis 
and hepatocellular carcinoma. Mitochondrial dysfunction, and in particular, 
diminished hepatic oxidative phosphorylation (OXPHOS) capacity, have been 
observed in NAFLD livers, which may participate in NAFLD pathogenesis.  
 
  To examine the role of OXPHOS in NAFLD, we generated a model of enhanced 
hepatic OXPHOS using mice with liver-specific transgenic expression of 
LRPPRC, a protein which activates mitochondrial transcription and augments 
OXPHOS capacity. When challenged with high-fat feeding, mice with enhanced 
hepatic OXPHOS were protected from the development of liver steatosis and 
inflammation, critical components in the pathogenesis of NAFLD. This protection 
corresponded to increased liver and whole-body insulin sensitivity. Moreover, 
mice with enhanced hepatic OXPHOS have increased availability of oxidized 
NAD+, which promotes complete fatty acid oxidation in hepatocytes. 
 
  Interestingly, mice with enhanced hepatic OXPHOS were also protected from 
obesogenic effects of long-term high-fat feeding. Consistent with this, enhanced 
hepatic OXPHOS increased energy expenditure and adipose tissue oxidative 
gene expression, suggesting a communication between the liver and adipose 
vii 
tissue to promote thermogenesis. Examination of pro-thermogenic molecules 
revealed altered bile acid composition in livers and serum of LRPPRC transgenic 
mice. These mice had increased expression of bile acid synthetic enzymes, 
genes which are induced by NAD+ dependent deacetylase SIRT1 activation of 
the transcriptional co-regulator PGC-1a. These findings suggest that enhanced 
hepatic OXPHOS transcriptionally regulates bile acid synthesis and dictates 
whole-body energy expenditure, culminating in protection from obesity. 
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CHAPTER I: INTRODUCTION 
 
Non-Alcoholic Fatty Liver Disease 
 
  Non-alcohol fatty liver disease (NAFLD) is becoming the most prevalent chronic 
liver disease in the modern world. Studies estimate that up to one third of the 
general population suffers from NAFLD (Bellentani et al., 2000; Bellentani et al., 
1994; Browning et al., 2004; Wanless and Lentz, 1990). The prevalence of 
NAFLD is increased in obese and diabetic patients, a striking 75% to 100% 
suffering from the disease. Previously thought to be a disease of overweight 
adults, NAFLD has been reported in children as young as four years old 
(Baldridge et al., 1995; Rashid and Roberts, 2000). As obesity rates continue to 
climb in both adult and pediatric populations, the incidence of NAFLD is expected 
to climb in parallel.   
  NAFLD represents a spectrum of disease (Fig. 1.1). In its mildest form, NAFLD 
is steatosis, or the deposition of fat within the liver (Angulo, 2002). However, as 
the disease progresses, it can predispose patients to more serious pathology 
including liver damage. Indeed, greater than 60% of asymptomatic elevations in 
serum liver enzymes are likely attributable to NAFLD (Ruhl and Everhart, 2003)). 
Additionally, between 10% and 30% of NAFLD patients have evidence of   
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Figure 1.1 NAFLD: a spectrum of disease. Nonalcoholic fatty liver disease 
spans from mild steatosis to florid inflammation and steatohepatitis. It is 
postulated that there are two “hits” in the progression to inflammation: the first 
metabolic, consisting of insulin resistance and lipid deposition, the second, 
inflammatory, with immune cell infiltration and fibrosis occurring. 
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inflammation, known as non-alcoholic steatohepatitis (NASH) (Minervini et al., 
2009; Wanless and Lentz, 1990; Williams et al., 2011), which can predispose 
patients to hepatocellular carcinoma (White et al., 2012). Due to its increasingly 
large prevalence, NAFLD poses substantial risk for these otherwise rare 
diseases. 
  Progression of fatty liver to steatohepatitis is likely multi-factorial and is not 
currently well understood. The existence of steatosis without progression to 
inflammation has led some to propose a “two-hit hypothesis” for the development 
of steatohepatitis (Day and James, 1998). In this model, lipid deposition initiates 
the disease, setting the stage for more serious hepatic pathology. The liver then 
succumbs to a second stressor, stimulating inflammation and fibrosis seen in 
NASH. Several candidates for this “second hit” have been proposed, including 
lipotoxicity, ER stress, adipose-tissue derived cytokines, activation of innate 
immunity, or gut-derived endotoxin (Maher et al., 2008; Neuschwander-Tetri, 
2010; Tilg and Moschen, 2010). In all cases, however, hepatocyte apoptosis and 
fibrosis are thought to be the final common pathway (Feldstein et al., 2003).  
Despite much research, the precise pathways which govern the onset of NASH 
remain elusive.  
  Beyond the liver, NAFLD predisposes patients to detrimental systemic 
pathology. NAFLD is an independent predictor of cardiovascular disease in 
diabetic patients, both type 1 and type 2 (Hamaguchi et al., 2007; Targher et al., 
2010; Targher et al., 2007) and increased transaminase levels are associated 
4 
with increased risk of mortality from cardiovascular events (Schindhelm et al., 
2007; Yun et al., 2009) Consistent with this, patients with NAFLD have been 
found to have increased endothelial cell dysfunction (Villanova et al., 2005), 
atherosclerosis (Brea et al., 2005; Choi et al., 2013; Wong et al., 2011), and 
cardiac remodeling and heart failure (Mantovani et al., 2015; VanWagner et al., 
2015). 
  Moreover, NAFLD is accompanied by diseases of metabolism. Patients with 
NAFLD are more likely to be insulin resistant than healthy individuals (Li et al., 
2015). Furthermore, NAFLD corresponds to an increased risk of Type II diabetes 
and metabolic syndrome (Adams et al., 2009; Zhang et al., 2014). Presence of 
steatosis has been shown to correlate with the degree of insulin resistance (Bae 
et al., 2010), and insulin resistance is the strongest predictive risk factor for 
NAFLD (Marchesini et al., 1999). This association suggests that metabolic 
dysfunction and NAFLD occur in parallel. Interestingly, accumulation of fat within 
the liver correlates with whole-body insulin resistance, independent of ectopic fat 
accumulation in peripheral tissues (Kato et al., 2014), implicating NAFLD as a 
causal factor in the onset of insulin resistance. Thus, understanding of the 
mechanisms behind the development and progression of NAFLD may give way 
to health benefits well beyond the liver itself. 
  Despite its prevalence, effective treatment modalities for NAFLD are lacking. 
Lifestyle interventions, such as diet and exercise induced weight loss, are 
effective in mitigating NAFLD’s effects, improving liver health (Bacchi et al., 2013; 
5 
Montesi et al., 2014; Wong et al., 2013; Zelber-Sagi et al., 2014), increasing 
insulin sensitivity (Haus et al., 2013; Oh et al., 2014; Petersen et al., 2005) and 
restoring cardiovascular function (Pugh et al., 2013; Pugh et al., 2014). However, 
these programs suffer from large attrition rates (Wadden et al., 1992) and are 
often ineffective in the ambulatory setting (Dudekula et al., 2014), making large-
scale implementation difficult. 
  In addition to weight loss, bariatric surgery has shown promise in the reversal of 
NAFLD. Several studies have reported improvements in hepatic steatosis and 
inflammation following bariatric surgery (de Andrade et al., 2008; Moretto et al., 
2012; Mummadi et al., 2008; Tai et al., 2012). However, others have found a 
worsening of fibrosis scores following weight loss surgery (Mathurin et al., 2009). 
Given the paucity of randomized clinical trials investigating the effectiveness 
bariatric surgery in this disease, formal assessment remains difficult (Chavez-
Tapia et al., 2010). Moreover, bariatric surgery is available to a limited population 
of NAFLD patients (CMS.gov, NCD 100.1) and carries risk for adverse events 
(Young et al., 2015). 
  Other agents, such as Vitamin E (Bugianesi et al., 2005; Lavine et al., 2011; 
Sanyal et al., 2010), metformin  (Bugianesi et al., 2005; Lavine et al., 2011), and 
ursodeoxycholic acid (Ratziu et al., 2011) have shown limited benefit. Thus, the 
search for effective and safe treatments for NAFLD remains an important area of 
focus for future research. 
  
6 
Metabolic Dysfunction in Fatty Liver 
 
  The liver stands at the center of whole-body metabolic regulation. Hepatocytes, 
the major parenchymal cell of the liver, are responsible for maintaining blood-
glucose levels through their ability to perform glycogenolysis and 
gluconeogenesis (Petersen et al., 1996). Additionally, the liver regulates 
cholesterol levels through its ability to both package and synthesize cholesterol 
de novo. Moreover, the production of bile acids by the liver plays an integral part 
in modulating cholesterol (Chiang, 2009). Via the use of cholesterol in bile acid 
synthesis, as well as promoting its intestinal absorption by secreted bile acids, 
the liver plays a critical role in cholesterol regulation. 
  Hepatic metabolism is regulated in large part by the opposing hormones insulin 
and glucagon (Saltiel and Kahn, 2001). Upon binding its receptor, insulin 
activates a signaling cascade in hepatocytes promoting an anabolic program and 
storage of energy as glycogen and triglyceride. Accordingly, catabolic programs 
such lipolysis and glycogenolysis, as well as gluconeogenesis, are inhibited by 
insulin signaling. Conversely, the downstream effects of glucagon signaling are 
to promote glucose export from the liver via glycogen breakdown and 
gluconeogenesis.  
  Many of these metabolic pathways are perturbed in NAFLD (Fig 1.2). Studies 
reveal an inability of NAFLD livers to down-regulate gluconeogenesis and  
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Figure 1.2 Hepatic metabolism is perturbed in fatty liver disease. Fatty acids 
within NAFLD livers are primarily derived from plasma non-esterified fatty acids 
(NEFA). Hepatic de novo lipogenesis also contributes to hepatic fatty acid levels. 
De novo lipogenesis may result increased serum insulin levels, which, in 
combination with other signals, such as amino acids or Notch signaling, stimulate 
the mammalian target of rapamycin complex 1 (mTORC1). mTORC1 activates 
sterol regulatory element binding protein (SREBP-1c), promoting lipogenesis. 
Increased liver fatty acids can result in excessive export as very low density 
lipoprotein (VLDL), a risk factor for atherosclerotic disease. Insulin normally 
inhibits forkhead box protein O1 (FOXO1), an activator of gluconeogenesis. 
However, in obesity and fatty liver, insulin’s action on this pathway is lost, 
permitting aberrant gluconeogenesis with simultaneous lipogenesis.  
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lipolysis in response to insulin (Marchesini et al., 2001; Sharma et al., 2009; 
Sunny et al., 2011). Consistent with these data, NAFLD severity correlates with 
decreases in insulin pathway signaling in obese patients (Ferreira et al., 2011). 
Paradoxically, this persistent gluconeogenesis is accompanied by an increase in 
triglyceride synthesis via de novo lipogenesis (Diraison et al., 2003; Donnelly et 
al., 2005), further highlighting the metabolic dysregulation in fatty liver disease. 
  NAFLD also promotes abnormal cholesterol metabolism. Lipidomic studies of 
NAFLD livers have demonstrated increased hepatic cholesterol levels (Puri et al., 
2007). Expression of the rate-limiting cholesterol synthetic enzyme HMGCR is 
also increased in NAFLD, and its expression correlates with hepatic cholesterol 
content (Caballero et al., 2009; Min et al., 2012). Min et al. also found an inverse 
correlation between hepatic low-density lipoprotein (LDL) receptor expression 
and serum LDL levels. Thus, both decreased absorption alongside increased 
synthesis promote dyslipidemia in NAFLD patients. 
  The following section details some of the potential mechanisms by which 
metabolic dysregulation occurs in NAFLD. 
   
Insufficient Fatty Acid Oxidation 
 The inability of livers to breakdown excess lipid may drive hepatic steatosis. 
Stable isotope experiments in NAFLD patients have demonstrated that 
approximately 60% of liver triglycerides arise from plasma fatty acids (Donnelly et 
al., 2005), suggesting an imbalance of lipid uptake and β-oxidative flux leading to 
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triglyceride accumulation. In support of this hypothesis, studies have found an 
accumulation of intermediate length fatty acyl-CoAs in fatty liver, suggesting 
incomplete oxidation of fatty acids (Eaton et al., 1996b; Satapati et al., 2012). 
Moreover, NAFLD patients have reduced levels of CPT1A, a gene critical for 
mitochondrial fatty acid import and oxidation (Kohjima et al., 2007). Thus 
complete fatty acid oxidation may be reduced in NAFLD. 
  Numerous studies have evaluated the important relationship between β-
oxidation and steatosis. Mouse models of diminished lipid oxidation by disruption 
of the oxidative enzymes LCAD, MCAD, or the mitochondrial trifunctional protein 
complex predispose mice to steatosis (Ibdah et al., 2005; Tolwani et al., 2005; 
Zhang et al., 2007). Additionally, loss of PPARα, a master regulator of the fatty 
acid oxidative gene program, promotes fatty liver in mice (Hashimoto et al., 2000; 
Kersten et al., 1999). 
  In contrast, enhancement of fatty acid oxidation has been shown to alleviate 
hepatic lipid burden. Activation of CPT1A-mediated flux into the mitochondria 
reduces the accumulation of lipids in the liver (Choi et al., 2007a). More, 
stimulation of the fatty acid oxidative program with PPARα agonists can reduce 
hepatic lipid burden from fasting (Chakravarthy et al., 2009; Chakravarthy et al., 
2005) and in genetically obese mice (Kim et al., 2003). The beneficial metabolic 
effects of these agonists in humans, however, may be independent of any effects 
on fatty liver (Fernandez-Miranda et al., 2008). 
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  Interestingly, fatty acid oxidation is, on the whole, increased in NAFLD patients 
(Iozzo et al., 2010), which indicates there is at least a partial compensatory 
response to lipid flux by the liver. Thus, it remains plausible that the physiologic 
upregulation of fatty acid oxidation is a limiting factor in NAFLD formation. 
 
Insulin Resistance 
Hepatic insulin resistance plays an important role in the progression of metabolic 
dysfunction. Mice with disrupted hepatic insulin signaling develop glucose 
intolerance and hyperinsulinemia (Michael et al., 2000). Similar to NAFLD 
patients, these mice also develop dyslipidemia and are prone to atherosclerotic 
disease (Biddinger et al., 2008). These studies underline the importance of 
hepatic insulin signaling in regulating glucose and cholesterol metabolism. The 
precise mechanism of insulin resistance in NAFLD remains a complex issue, 
however. 
    The accumulation of hepatic lipids is likely a critical factor in the development 
of insulin resistance (Fig 1.3). Specifically, multiple studies have demonstrated 
that levels of hepatic diacylglycerol (but not other lipids) in the liver directly 
correlate with insulin resistance in NAFLD patients (Kumashiro et al., 2011; 
Magkos et al., 2012). Diacylglycerol is capable of activating novel isoforms of 
protein kinase C (PKC) independent of cellular calcium (Leibersperger et al., 
1990; Liyanage et al., 1992; Nishizuka, 1992; Ohno et al., 1988; Shirai et al., 
1998).   
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Figure 1.3 Fatty acid metabolism is linked to insulin resistance in liver. In 
healthy liver, fatty acids absorbed from the blood stream undergo catalysis via β-
oxidation and the TCA cycle, generating NADH to fuel ATP synthesis at the 
electron transport chain. In states of metabolic excess, however, this system can 
be overwhelmed, increasing the relative concentration of reduced NADH, which 
inhibits further oxidation. This can lead to deposition in of fatty acids in the 
cytoplasm as diacylglycerol (DAG). DAG activates protein kinase C epsilon 
(PKCε), which impedes insulin signaling. Additionally, increased flux of NADH at 
Complex I of the electron transport chain induces the formation of superoxide 
(O2-), increasing reactive oxygen species (ROS) further inhibiting insulin 
signaling. 
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In fatty liver, diacylglycerol activates protein kinase C which phosphorylates the 
insulin receptor blocking downstream signaling (Bezy et al., 2011; Considine et 
al., 1995; Lam et al., 2002; Samuel et al., 2004; Samuel et al., 2007). 
Importantly, interventions which target diacylglycerol levels (Cantley et al., 2013; 
Choi et al., 2007b; Samuel et al., 2007; Savage et al., 2006) or PKC activity 
(Greene et al., 2014; Samuel et al., 2007) improve insulin sensitivity. 
Nonetheless, some have questioned this hypothesis, as other models have 
demonstrated a dissociation between hepatic diacylglycerol content and insulin 
resistance (Brown et al., 2010; Hall et al., 2014; Monetti et al., 2007; Ong et al., 
2013; Sun et al., 2012). 
  Increased oxidative stress could also promote insulin resistance in NAFLD. The 
formation of reactive oxygen species can disrupt normal insulin signaling (Hoehn 
et al., 2009; Houstis et al., 2006). Moreover, studies investigating NAFLD livers 
have demonstrated evidence of oxidative load (Feldstein et al., 2010; Konishi et 
al., 2006; Loguercio et al., 2001; Seki et al., 2002; Videla et al., 2004; Yesilova et 
al., 2005). Some studies have suggested oxidative stress attenuates insulin 
signaling through activation of c-Jun N-terminal Kinase (JNK) (Kamata et al., 
2005) leading to inhibitory phosphorylation of insulin receptor substrate (IRS) 
molecules at serine residues (Aguirre et al., 2000; Aguirre et al., 2002; Lee et al., 
2003). However, inhibiting serine phosphorylation of IRS molecules in liver 
curiously promotes insulin resistance (Copps et al., 2010), which suggests 
oxidative stress may mediate hepatic insulin resistance through an alternative 
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pathway. Additionally, there is evidence that oxidative stress improves insulin 
sensitivity (Berdichevsky et al., 2010; Loh et al., 2009), which may indicate that 
subcellular location and/or timing of reactive oxygen species formation has 
varying effects on insulin signaling. Nonetheless, the potential role of oxidative 
stress in NAFLD remains a subject of interest. 
  Hepatic insulin resistance may occur as a result of inflammation. Inflammation 
has long been linked to obesity and insulin resistance (Feinstein et al., 1993; 
Fried et al., 1998; Hotamisligil et al., 1995; Hotamisligil et al., 1996; Hotamisligil 
et al., 1993; Samad et al., 1997; Sartipy and Loskutoff, 2003; Weisberg et al., 
2003). Supporting a role for inflammation impairing hepatic insulin signaling, IL-6 
induces insulin resistance in hepatocytes (Kim et al., 2004; Klover et al., 2005; 
Sabio et al., 2008; Senn et al., 2002). Moreover, liver inflammation induces both 
tissues-specific and whole-body insulin resistance (Arkan et al., 2005; Cai et al., 
2005; Ueki et al., 2004) and treatment with anti-inflammatory compounds has 
been shown to improve insulin signaling (Reid and Lightbody, 1959; Yuan et al., 
2001). Despite this, randomized controlled trials of anti-inflammatories have 
revealed only modest effects, (Goldfine et al., 2013), suggesting insulin 
resistance may be multifactorial in its pathophysiology. 
  Endoplasmic reticulum (ER) stress is yet another mechanism which has been 
implicated in insulin resistance. Livers of high-fat diet fed mice demonstrated 
increased ER stress compared to chow-fed controls (Ozcan et al., 2004). 
Additionally, mice with increased ER stress are predisposed to insulin resistance 
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(Yang et al., 2000) and prevention of ER stress by molecular or chemical 
chaperones preserves insulin signaling in mice (Nakatani et al., 2005; Ozcan et 
al., 2006). Curiously, the physiologic response to ER stress has been shown to 
inhibit gluconeogenesis via activation of ATF6 (Seo et al., 2010; Wang et al., 
2009). At least one study has shown a reduction in ATF6 levels in chronic 
obesity, however, which may explain how this response is blunted in fatty liver 
(Wang et al., 2009). The presence of ER stress in human NAFLD has been 
contested, as multiple studies have found no association of steatosis with 
upregulation of the ER stress response [though ER stress was observed NASH] 
(Gonzalez-Rodriguez et al., 2014; Kumashiro et al., 2011; Lake et al., 2014).  
  Data also suggest the accumulation of ceramides may diminish insulin 
sensitivity. Ceramide species are thought to interfere with normal insulin 
signaling by inhibition of AKT either through phosphorylation by PKCζ (Fox et al., 
2007; Powell et al., 2003) or via activation of protein phosphatase 2A (Chavez et 
al., 2003; Schubert et al., 2000). In keeping with this hypothesis, inhibition of 
ceramide synthesis reverses insulin resistance caused by a number of 
physiologic stressors, including glucocorticoid treatment, lipid infusion, and 
genetic obesity (Holland et al., 2007). However, ceramide concentrations are 
only marginally altered in fatty liver (Turinsky et al., 1990) and, like markers of ER 
stress, do not correlate with insulin resistance in humans (Kumashiro et al., 
2011), thereby clouding the picture of their role in NAFLD. 
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Unchecked Lipogenesis 
  In healthy livers, lipogenesis occurs in the fed state. Rising serum insulin levels 
activate the insulin receptor, initiating a downstream cascade and subsequent 
activation of the transcription factor sterol regulatory element binding protein 
(SREBP-1c) (Horton et al., 1998; Kim et al., 1998). Upon activation, SREBP1c 
translocates to the nucleus and promotes transcription of lipogenic genes (Foretz 
et al., 1999; Liang et al., 2002; Matsuda et al., 2001). In the absence of insulin 
signaling, such as in fasting, SREBP-1c remains inactivated and de novo 
lipogenesis does not occur (Horton et al., 1998; Kim et al., 1998). Thus, through 
the action of insulin on SREBP-1c the liver responds to variations in nutrient 
availability. 
  The mechanism of activated lipogenesis in NAFLD has garnered much 
attention. Paradoxically, SREBP-1c remains activated in obese livers despite 
hepatic insulin resistance (Bae et al., 2012; Pettinelli et al., 2009; Shimomura et 
al., 1999; Shimomura et al., 2000). The precise mechanism by which this occurs 
is not completely understood. Insulin stimulates SREBP-1c via the mammalian 
target of rapamycin complex 1 (mTORC1) (Duvel et al., 2010; Porstmann et al., 
2008). Highlighting its importance in this process, disruption of hepatic mTORC1 
signaling prevents the onset of steatosis after high-fat feeding (Bae et al., 2012). 
Interestingly, insulin regulates lipogenesis independent of its action of 
gluconeogenesis (Li et al., 2010b). This suggests a branch point with varying 
susceptibility to insulin resistance, leaving lipogenic stimuli intact while 
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suppression of gluconeogenesis is defective. Consistent with this notion, patients 
with mutations at the insulin receptor have normal lipogenic activities, whereas 
lipodystrophic patients and those with AKT2 mutations have increased de novo 
lipogenesis (Semple et al., 2009). Thus, insulin resistance may affect distinct 
pathways downstream of the insulin receptor, resulting in activation of 
lipogenesis. 
  Others have suggested that regulation of gluconeogenesis in NAFLD is 
independent of the canonical insulin signaling pathway. While mice lacking 
hepatic AKT1 and AKT2 fail to respond appropriately to insulin, deletion of the 
downstream gluconeogenic regulator FOXO1 restores insulin responsiveness in 
these mice (Lu et al., 2012). Additionally, loss of FOXO1 restores insulin 
sensitivity in insulin receptor deficient livers (Titchenell et al., 2015), further 
indicating that insulin regulates gluconeogenesis via a liver-independent pathway 
in vivo. Consistent with this notion, Perry et al. demonstrated that suppression of 
adipocyte lipolysis mitigates hepatic glucose production in high-fat fed animals 
(Perry et al., 2015a). In this study, levels of hepatic acetyl-CoA were shown to 
correlate with adipose lipolysis and hepatic gluconeogenesis, further suggesting 
a role for adipose derived nutrients in regulating gluconeogenesis. Indeed, 
infusion of acetyl-CoA precursors eliminated the insulin sensitivity bestowed by 
knockout of AKT1/2 and FOXO1 in livers. Together, these data indicate that 
excess gluconeogenesis in obesity may derive from increased adipose lipolysis, 
independent of insulin signaling within the liver.   
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  Activation of SREBP1c may occur through insulin independent mechanisms as 
well. Nutrients, such as amino acids, can activate mTORC1 signaling (Kim et al., 
2002). Moreover, amino acids are elevated in obese and diabetic patients (Felig 
et al., 1969; Newgard et al., 2009; Wang et al., 2011b; Wurtz et al., 2012), which 
could stimulate mTOR mediated hepatic lipogenesis. Recent studies in mice 
indicate that hepatic Notch signaling may also activate mTORC1 and lipogenesis 
(Pajvani et al., 2013). Notch is activated in fatty liver (Valenti et al., 2013), 
perhaps providing another mechanism by which lipogenesis is activated in 
NAFLD. 
  ER stress may also regulate lipogenesis in liver. Mice lacking XBP-1, a protein 
activated by ER stress, had reduced levels of lipogenic enzyme expression (Lee 
et al., 2008). Expression of GRP78, a molecular chaperone, also reduced 
steatosis and lipogenic gene expression in ob/ob mice (Kammoun et al., 2009). 
Moreover, blocking phosphorylation of ER stress-responsive eIF2α prevented 
steatosis, though the lipogenic program was not formally assessed (Oyadomari 
et al., 2008).  In contrast, however, induction of ER stress with tunicamycin 
reduces liver expression of SREBP-1c and downstream targets (Rutkowski et al., 
2008). Mice in this study sensitized to ER stress by loss of ATF6 or p58 
developed steatosis without alterations in SREBP-1 or downstream lipogenic 
genes, suggesting ER stress can promote hepatic lipid accumulation through 
SREBP-1 independent mechanisms.  The precise role of ER stress in the 
regulation of lipogenesis, thus, remains unclear. 
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Altered Redox State 
  Proper functionality of cells requires the availability of electron carrier 
intermediates to support the plethora of redox reactions involved in metabolic 
reactions. One such electron carrier, nicotinamide adenine dinucleotide (NAD+), 
is of particular interest due to its intimate relationship with glucose and lipid 
metabolism. Oxidized NAD+ is an essential co-factor for glycolysis and fatty acid 
beta-oxidation, while its reduced form, NADH, provides electrons to the electron 
transport chain to generate a proton motive force for ATP synthesis (Vella, 1994). 
Moreover, increases in the ratio of NADH:NAD+ directly correlate with the 
generation of reactive oxygen species (Kussmaul and Hirst, 2006), further tying 
redox state to cellular function.  
  Recent studies have revealed a critical role for the NAD+ sensitive Sirtuin class 
of de-acetylases in the regulation of hepatic metabolism (Chang and Guarente, 
2014; Hall et al., 2013). Sirtuin 1 (SIRT1) plays a critical role in induction of 
gluconeogenic genes and inhibition of de novo lipogenesis (Ponugoti et al., 2010; 
Rodgers et al., 2005; Rodgers and Puigserver, 2007). Furthermore, loss of 
SIRT1 has been shown to promote fatty liver in mice (Purushotham et al., 2009; 
Wang et al., 2011a; Xu et al., 2010), indicating activation of this pathway by 
NAD+ is critical for homeostatic maintenance. Additionally, the mitochondrial 
sirtuin, SIRT3, functions to deacetylate mitochondrial proteins, promoting cellular 
respiration (Ahn et al., 2008; Hirschey et al., 2010; Liu et al., 2014; Shimazu et 
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al., 2010), though its function in liver metabolism may not be as critical as it 
initially appeared (Fernandez-Marcos et al., 2012).  
  Consistent with altered redox states in fatty liver, studies in mice have found a 
decrease in NAD+/NADH ratio in the livers of obese mice (Kendrick et al., 2011; 
Kim et al., 2011; Yoshino et al., 2011). This may in part be due to reduced 
expression of the essential NAD+ biosynthetic enzyme NAMPT (Yoshino et al., 
2011). Moreover, Kendrick et al. demonstrated reduced SIRT3 activity and 
hyperacetylation of mitochondrial proteins in fatty liver, implying reduced NAD+ 
has physiologic effects (Kendrick et al., 2011). Of note, treatment of obese mice 
with NAD+ precursors was capable of restoring insulin sensitivity, however, the 
precise effects on fatty liver were not examined (Canto et al., 2012; Yoshino et 
al., 2011). Nonetheless, these data indicate that altered redox state may play an 
important part in altered hepatic metabolism during obesity. 
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Hepatic Cross-talk with Adipose Tissue 
 
  The role of the liver in metabolism has expanded to one of whole-body 
energetic regulation due to the discovery of hepatocyte-derived molecules which 
influence organismal energy balance. These so-called “hepatokines” are of 
therapeutic interest due to their ability to stimulate energy expenditure and 
induce insulin sensitivity. Additionally, their potential dysregulation in NAFLD may 
connect the onset of liver disease and whole-body metabolic dysfunction. Data 
from patients provide some support for a liver centered model. A cohort study 
assessing PET-CT activation of adipose thermogenesis revealed an inverse 
association between NAFLD and functional brown adipose tissue (Yilmaz et al., 
2011). Thus, perhaps hepatokines provide a link between liver and whole body 
metabolism in NAFLD. 
  Fibroblast growth factor 21 (FGF21) is one such hepatokine. Expressed at high 
levels in the liver (Nishimura et al., 2000), FGF21 was identified in a screen for 
molecules which activate glucose uptake in adipose cell lines and was shown to 
protect from the effects of a high-fat diet (Kharitonenkov et al., 2005). The 
precise mechanism of FGF21-mediated protection is unclear, as while it induces 
browning of adipose tissue (Kharitonenkov et al., 2005), its ability to counteract 
diet-induced obesity is independent of UCP1 (Samms et al., 2015; Veniant et al., 
2015). Additionally, central nervous system response seems to be an important 
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component for the effect of FGF21 (Owen et al., 2014). Nevertheless, FGF21 
has arisen as a potential mediator of whole body metabolism in mice. 
  The role of FGF21 in humans, however, may not be as clear. Numerous studies 
have demonstrated an increase in circulating FGF21 levels in obesity and 
NAFLD (Bobbert et al., 2013; Chavez et al., 2009; Dasarathy et al., 2011; Li et 
al., 2010a; Li et al., 2011c; Zhang et al., 2008). These findings may indicate 
some level of receptor resistance in humans, which has not been seen in mice 
(Hale et al., 2012). Whether or not FGF21 upregulation offers a protective benefit 
in human obesity is still unclear. Furthermore, while preclinical trials in animals 
are promising (Adams et al., 2013; Veniant et al., 2012), clinical trials have had 
only modest effects (Gaich et al., 2013). Thus, though FGF21 connects hepatic 
metabolic status with whole body energy expenditure, its benefit in human 
obesity remains to be determined. 
  Bile acids may also play a role in regulating whole body energy status. The 
ability for bile acids to auto-regulate via a feedback mechanism long been 
understood (Pandak et al., 1991; Ramirez et al., 1994). However, the discovery 
of bile acid receptors which participate in numerous metabolic pathways has 
expanded their role in physiology (Kawamata et al., 2003; Makishima et al., 
1999; Maruyama et al., 2002; Parks et al., 1999; Wang et al., 1999). The bile-
acid activated nuclear receptor FXR is essential in regulation of bile acid 
synthesis through attenuating the expression of CYP7A1, the rate limiting 
synthetic enzyme This occurs both through FXR-mediated secretion of FGF19 
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(FGF15 in mice) by enterocytes as well as direct action on FXR in hepatocytes 
(Chen et al., 2001; Chiang et al., 2000; Goodwin et al., 2000; Holt et al., 2003; 
Inagaki et al., 2005; Li et al., 2014; Lu et al., 2000; Song et al., 2009). Activation 
of FXR in both the liver and intestine have been shown to enhance insulin 
sensitivity, reduce lipogenesis, and counteract fatty liver disease (Cariou et al., 
2006; Fang et al., 2015; Watanabe et al., 2004; Zhang et al., 2006). Thus, FXR 
represents a potential therapeutic mechanism by which bile acids modulate 
disease. 
  Additionally, bile acids activate TGR5, a novel G-protein coupled receptor 
expressed in a number of tissues (Kawamata et al., 2003; Maruyama et al., 
2002). Activation of TGR5 promotes adipose thermogenesis via induction of local 
thyroid hormone production (Watanabe et al., 2006). TGR5 also promotes GLP-1 
secretion and enhances insulin sensitivity in mice fed a high-fat diet (Thomas et 
al., 2009). Importantly, studies in humans indicate that bile acids can activate 
brown adipose thermogenesis, further supporting TGR5 activation may be 
beneficial in obesity (Broeders et al., 2015). Thus, via regulation of FXR and 
TGR5, bile acids may function to modulate energy expenditure, thereby 
connecting hepatic metabolism to regulation of whole-body energy homeostasis.  
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Mitochondria and Disease 
 
  The hypothesis that mitochondrial dysfunction stands at the center of disease 
stems from Denham Harman’s theory of free radical theory of aging (Harman, 
1956). In his landmark paper, Harman proposed that oxygen radicals, most likely 
derived from respiratory enzymes, were the major determinant of cellular and 
organismal aging. He and others later expanded on this idea, suggesting that 
mitochondrial dysfunction specifically mediates aging and disease (Fleming et 
al., 1982; Harman, 1972; Miquel et al., 1980; Wallace, 2013; Wallace et al., 
1999). In essence, the accumulation of oxidative stress over a long period of time 
causes damage to molecules essential for mitochondrial function – mitochondrial 
DNA, membrane phospholipids, or proteins – thereby reducing cellular 
functionality.  
  This theory is supported by several lines of evidence. Mitochondria have great 
capacity to produce reactive oxygen species (Boveris and Cadenas, 1975; 
Boveris and Chance, 1973; Boveris et al., 1972). Additionally, oxidative damage 
and mutations in mitochondrial DNA have been shown to accumulate with age 
(Cortopassi and Arnheim, 1990; Hattori et al., 1991; Mecocci et al., 1993). In 
accordance with this finding, aging is associated with reduced mitochondrial 
respiratory capacity (Muller-Hocker, 1989; Petersen et al., 2003; Short et al., 
2005; Trounce et al., 1989). Thus, it is plausible that accumulations of mtDNA 
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mutations (or other reactive oxygen species-induced modifications) could 
promote mitochondrial dysfunction in aging. 
  Further data from cellular and animal model systems support a role for 
mitochondrial dysfunction in age-related health decline. Mice with a defective 
mitochondrial polymerase accumulate mtDNA mutations and age prematurely 
(Edgar et al., 2009; Trifunovic et al., 2004; Vermulst et al., 2008). Additionally, 
reduction of mitochondrial reactive oxygen species formation extends life in 
animal models (Melov et al., 2000; Orr and Sohal, 1994; Sampayo et al., 2003; 
Schriner et al., 2005; Sun et al., 2002). However, these results are not uniformly 
reproducible (Keaney and Gems, 2003; Orr et al., 2003) which raises some 
question as to the precise role of oxidative stress in longevity. Nevertheless, the 
relationship between mitochondrial dysfunction and diseases of aging is 
intriguing. 
 
  Mitochondrial Dysfunction and Metabolism 
  The mitochondrion is an unique target in metabolic dysfunction due to its 
multifaceted intersection with cellular metabolism. Indeed, for over 50 years, 
researchers have held an interest in mitochondrial function in the diabetic state 
(Hall et al., 1960; Parks et al., 1955; Vester and Stadie, 1957). Through its ability 
to generate large amounts of ATP, the mitochondrion provides energy for 
essential anabolic pathways. Accordingly, the metabolism of both glucose and 
fatty acids terminates at the mitochondrial respiratory chain. Mitochondria also 
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serve to replenish oxidized electron carrier intermediates, necessary co-factors in 
many metabolic pathways. Given the intimate relationship with cellular 
metabolism, the mitochondrion represents an important subject of study in the 
field of metabolism. 
  Investigation has revealed the presence of mitochondrial dysfunction in human 
metabolic disorders. Shulman and colleagues demonstrated that insulin-resistant 
patients have diminished myocellular ATP synthesis (Petersen et al., 2004). 
Additionally, insulin resistance is associated with a reduction in mitochondrial 
density in muscle (Morino et al., 2005). Multiple studies demonstrated a reduction 
in the expression of OXPHOS genes in diabetic muscle (Mootha et al., 2004; 
Mootha et al., 2003b; Patti et al., 2003), further implicating the respiratory chain 
in the onset of insulin resistance. 
  The respiratory chain and OXPHOS may interact with metabolism at many 
levels (for a discussion on mechanisms of insulin resistance, see page 10). 
Specifically, complex I and III of the respiratory chain are primary sources of 
reactive oxygen species, which have been shown to interfere with insulin 
signaling (Chen et al., 2003; Liu et al., 2002; St-Pierre et al., 2002). Additionally, 
deficiencies in OXPHOS result in a reduction of the NAD+/NADH ratio (Eaton et 
al., 1996a), which can prevent metabolic flux through catabolic pathways. 
Accordingly, defects in OXPHOS result in deficient β-oxidation of fatty acids 
(Watmough et al., 1990) which could promote the accumulation of deleterious 
26 
lipid byproducts such as diacylglycerol. Thus, OXPHOS activity per se may 
influence the onset of insulin resistance and perturb metabolism. 
   
OXPHOS in NAFLD 
 Mitochondrial dysfunction is an apparent feature in NAFLD. Electron microscopy 
in livers of both NAFLD and NASH patients revealed dysmorphic rounded 
mitochondria with reduced cristae density (Ahishali et al., 2010; Caldwell et al., 
1999; Sanyal et al., 2001). Consistent with this, functional studies have further 
demonstrated an inability of these patients to recuperate hepatic ATP stores and 
a reduction of mitochondrial complex activity (Cortez-Pinto et al., 1999; Perez-
Carreras et al., 2003), indicative of dysfunctional OXPHOS. Interestingly, 
expression of nuclear encoded OXPHOS subunits is elevated in NAFLD livers, 
revealing a discordance between nuclear gene expression and OXPHOS 
functionality (Misu et al., 2007; Takamura et al., 2008). 
  Mouse models of NAFLD corroborate an OXPHOS deficiency in fatty liver. In 
mice fed a high-fat diet, reductions in Cytochrome C expression precede the 
onset of steatosis and insulin resistance (Rector et al., 2010). Similarly both 
ob/ob mice and mice fed a HFD have reduced individual respiratory complex 
activity (Garcia-Ruiz et al., 2006; Garcia-Ruiz et al., 2014). Interestingly, while 
high fat fed mice had equivocal expression of nuclear encoded OXPHOS genes, 
mitochondrially encoded subunits were uniformly reduced, perhaps offering an 
explanation for the apparent discordance in patient studies(Garcia-Ruiz et al., 
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2014). Taken together, these data indicate OXPHOS is deficient in NAFLD. We, 
thus, hypothesized that dysfunctional OXPHOS contributes to fatty liver 
disease. We reasoned that restoration of hepatic OXPHOS may mitigate 
fatty liver. To test this hypothesis, we sought a mechanism by which to 
augment hepatic OXPHOS. 
 
Regulation of OXPHOS 
  Mitochondrial biogenesis is a one means to regulate OXPHOS levels. The 
nuclear respiratory factors (NRF-1 and NRF-2) can induce expression of the 
mitochondrial transcription factor TFAM and expression of respiratory genes 
(Evans and Scarpulla, 1990; Virbasius and Scarpulla, 1994). Interestingly, liver-
specific knockout of NRF-1 results in steatohepatitis and liver cancer (Xu et al., 
2005). It should be noted, however that loss of NRF-1 was associated with a 
marked reduction in glutathione synthetic enzyme expression, making 
extrapolation of the role of OXPHOS in this model difficult.  
  The estrogen-related receptor family (ERR-α, -β, and -γ) has been shown to 
participate in the regulation of numerous metabolic processes (Eichner and 
Giguere, 2011), including mitochondrial biogenesis (Mirebeau-Prunier et al., 
2010; Schreiber et al., 2004). Unfortunately, there is a dearth of genetic models 
studying the liver-specific roles of ERR genes. Whole body knockouts of ERRα 
were protected from the effects of a high-fat diet (Luo et al., 2003), though these 
mice did have increased susceptibility to diethylnitrosamine-induced 
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hepatocellular carcinoma (Hong et al., 2013). Conversely, Choi and colleagues 
demonstrated that ERRγ promotes gluconeogenesis, and that inhibition with an 
inverse agonist reversed hyperglycemia (Kim et al., 2013; Kim et al., 2012). 
Thus, the role of the estrogen-related receptor family in liver pathology is difficult 
to interpret. Moreover, like the nuclear respiratory factors, ERRs activate a 
plethora of metabolic pathways, which could confound their use in manipulation 
of OXPHOS. 
  The discovery of peroxisome proliferator-activated receptor gamma (PPARγ) 
co-activators revealed a family of transcriptional co-activators which can 
influence mitochondrial biogenesis. The initial family member, PPARγ Co-
activator-1α (PGC-1α), was identified in yeast two-hybrid for interaction partners 
with PPARγ (Puigserver et al., 1998). Since then, two additional members, PGC-
1β and PGC-1-related coactivator (PRC) have been identified (Andersson and 
Scarpulla, 2001; Lin et al., 2002). A multitude of studies support the role of these 
factors in mitochondrial biogenesis, in part via co-activation of NRF and ERR 
transcription factors (Gleyzer et al., 2005; Mootha et al., 2004; Schreiber et al., 
2004; Schreiber et al., 2003; Shao et al., 2010; Uldry et al., 2006).  
  Examination of the roles PGC family members play in hepatic metabolism has 
revealed mixed results. While mice heterozygous for PGC-1α had increased liver 
triglyceride, cholesterol, and insulin resistance (Estall et al., 2009), another model 
revealed improved insulin sensitivity with PGC-1α knockdown (Koo et al., 2004). 
On the other hand, expression of a PGC-1β hypomorph led to hepatic insulin 
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resistance (Vianna et al., 2006). Moreover, liver-specific knockout of PGC-1β 
reduced hepatic fatty acid oxidative gene expression with concordant increases 
in lipid accumulation (Chambers et al., 2012). However, despite lowering hepatic 
lipid levels, PGC-1β overexpression increases serum VLDL levels (Lelliott et al., 
2007), limiting its therapeutic potential. Altogether, these data suggest that, while 
they promote cellular respiration, regulators of mitochondrial biogenesis 
participate in numerous, often confounding, pathways, making their use in the 
study of OXPHOS less desirable. 
  Functional OXPHOS requires the coordinated expression of two genomes. 
Each mitochondrion is endowed with between two and ten copies of a circular 
genome, approximately 16kb in length. Mitochondrial DNA (mtDNA) encodes for 
13 polypeptides of the electron transport chain and ATP synthase, as well as 
mitochondrial ribosomal and tRNA (Falkenberg et al., 2007). The remainder of 
the approximately 100 proteins required for functional oxidative phosphorylation 
(OXPHOS) are encoded in the nuclear genome. Expression of the mitochondrial 
genome is essential for the maintenance of mature OXPHOS complexes. 
Importantly, mutations in either nuclear or mitochondrially encoded OXPHOS 
genes can result in mitochondrial dysfunction (Leonard and Schapira, 2000a, b), 
highlighting the essential nature of each genome. 
  Transcription of the mitochondrial genome is initiated by the binding of a 
transcriptional complex (Fig. 1.4). Binding by the mitochondrial specific RNA 
polymerase (POLRMT) and the mitochondrial specific transcription factor TFB2M   
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Figure 1.4 Transcription of mtDNA regulates OXPHOS. A)Transcription of 
mtDNA requires the basal transcriptional machinery: the polymerase (POLRMT) 
and a transcription factor (TFB2). Mitochondrial transcription can be potentiated 
by addition of the transcriptional co-activator LRPPRC. (Figure adapted from Liu 
L et al., J. Biol Chem, 2011). B) Contribution of mitochondrially encoded genes to 
each of the five respiratory chain components. Numerator indicates the number 
of mitochondrially encoded subunits (listed below), denominator represents total 
subunits.  
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promotes transcription (Falkenberg et al., 2002; Gaspari et al., 2004; Shutt et al., 
2010; Sologub et al., 2009). A third component, TFAM, may be necessary for 
transcription initiation, however, data suggest its role is primarily mtDNA 
maintenance and transcriptional co-activation (Ekstrand et al., 2004; Kaufman et 
al., 2007; Litonin et al., 2010; Shi et al., 2012; Shutt et al., 2011). Consistent with 
a primary role in genomic stability, mice with transgenic expression of human 
TFAM had increased levels of mtDNA without alterations in COX1 expression or 
OXPHOS respiratory capacity (Ekstrand et al., 2004). 
  Transcription of the mitochondrial genome is coupled to translation and 
insertion of OXPHOS subunits into the mitochondrial membrane. Mitochondrial 
transcriptional complexes are thought to exist in a complex with translational 
machinery at the inner mitochondrial membrane. In support of this, both the 
mitochondrial genome has been found to associate with inner mitochondrial 
membrane (Albring et al., 1977). Additionally, data suggest proteins involved in 
mitochondrial mRNA stability and translation exist in membrane-bound 
complexes (Krause et al., 2004) and associate with the mitochondrial RNA 
polymerase (Rodeheffer et al., 2001). Furthermore, mutations which interfere 
with polymerase binding to these membrane-bound RNA stabilizing proteins 
blocks mitochondrial translation (Rodeheffer and Shadel, 2003). Taken together, 
these data indicate a tight regulation of OXPHOS complex formation by 
mitochondrial transcription. 
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  Few studies have examined the role of OXPHOS in NAFLD. Though not bona 
fide OXPHOS, data indicate that enhanced cellular respiration is beneficial to 
fatty liver. Historically, mitochondrial uncoupling agents, such as dinitrophenol, 
have been employed as weight loss agents given their ability to depolarize the 
mitochondrial membrane, expending stored energy as heat (Dunlop, 1934). [This 
practice was discontinued, however, due to the unfortunate side effect of 
hyperthermic crisis and death. (Tainter and Wood, 1934)]  Nonetheless, studies 
using mitochondrial uncoupling agents in mice have revealed beneficial effects – 
lowering of hepatic lipid burden, reduction of diacylglycerol, and improved insulin 
sensitivity (Perry et al., 2013; Perry et al., 2015b; Samuel et al., 2004; Tao et al., 
2014). These studies indicate that cellular respiration, even at the expense of 
ATP, is sufficient to counteract NAFLD. 
  Pospisilik et al. studied the metabolic effects of deficient OXPHOS using a liver-
specific AIF deficient (LAIFKO) mouse (Pospisilik et al., 2007). LAIFKO mice had 
moderate deficiencies in complex I and complex V of the respiratory chain 
resulting in a significant reductions in respiratory capacity. Interestingly, when 
challenged with a high fat diet, LAIFKO mice were more insulin sensitive than 
wild-type controls. However, these mice also demonstrated a significant 
reduction in weight, an important component of whole body metabolism. 
Consistent with this finding, loss of hepatic OXPHOS by either constitutive (using 
albumin-Cre) or acute (using AAV-TBG-Cre) excision of the mitochondrial 
transcriptional regulator LRPPRC [reviewed in detail below] results in significant 
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weight loss (Cooper Lab, unpublished data). These data may indicate a 
confounding effect of respiratory deficiency within the liver that could explain the 
observations by Pospisilik et al. Moreover, the role of physiologic OXPHOS 
dysfunction in NAFLD remains unclear. 
 
LRPPRC: a Regulator of OXPHOS 
  Leucine rich pentatricopeptide repeat containing protein (LRPPRC; also 
LRP130) was originally identified as a leucine-rich wheat-germ lectin binding 
protein in HepG2 cells (Hou et al., 1994). Mutations of LRPPRC were later 
shown to cause the rare mitochondrial disease Leigh Syndrome, French 
Canadian type (LSFC) (Mootha et al., 2003a). Discovered in the Saguenay Lac-
Saint-Jean region of Quebec, LSFC results in mitochondrial dysfunction due to a 
pronounced COX deficiency (Merante et al., 1993; Morin et al., 1993; Xu et al., 
2004). These patients suffer from delayed development, abnormal facies, hepatic 
steatosis, and lactic acidosis. Sadly, due to severe acidotic crises, patients with 
LSFC typically do not live beyond adolescence. 
 Reports have suggested LRPPRC localizes in both the nucleus as well as the 
mitochondrion (Cooper et al., 2006; Mili and Pinol-Roma, 2003; Xu et al., 2004). 
The primary role for LRPPRC, however, is thought to be in the mitochondrion, 
where it regulates the expression of mitochondrially encoded OXPHOS subunits. 
This is thought to be via its ability to activate transcription of the mitochondrial 
genome (Cooper et al., 2006; Cooper et al., 2008; Liu et al., 2014; Liu et al., 
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2011; Sondheimer et al., 2010) or through its ability to stabilize mitochondrially 
encoded transcripts (Gohil et al., 2010; Lagouge et al., 2015; Sasarman et al., 
2010; Xu et al., 2004). Activation of LRPPRC in liver induces the mitochondrial 
response to fasting, supporting fatty acid oxidation and ketogenesis (Liu et al., 
2014; Liu et al., 2011). Moreover, ectopic expression of LRPPRC in liver 
promotes cellular respiration and ATP synthesis, indicative of bona fide OXPHOS 
(Liu et al., 2011). Importantly, the effects of LRPPRC are independent of 
alterations in mitochondrial mass, suggesting its effects are independent of 
mitochondrial biogenesis. This makes LRPPRC a useful tool in the analysis of 
OXPHOS in metabolic disease. 
  We propose to examine the role of OXPHOS in NAFLD by utilizing 
LRPPRC. In order to generate a model of enhanced hepatic OXPHOS in 
NAFLD livers, we established a transgenic mouse line with liver-specific 
overexpression of LRPPRC. The goal of these studies is to investigate the 
effect of enhanced hepatic OXPHOS on fatty liver disease. 
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CHAPTER II: DETERMINATION OF FATTY ACID OXIDATION AND 
LIPOGENESIS IN MOUSE PRIMARY HEPATOCYTES 
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Introduction 
 
  Non-alcoholic fatty liver disease is one of the leading causes of liver disease in 
Westernized cultures (Clark et al., 2003; Lazo et al., 2013). Lipid accumulation 
within the liver is associated with cell death, fibrosis, and liver failure via yet 
unknown mechanisms (Adams et al., 2005; Angulo, 2002; Day and James, 1998; 
Feldstein et al., 2003). In fatty liver disease, hepatocyte-mediated β-fatty acid 
oxidation and de novo lipogenesis are important determinants of net lipid 
accumulation (Donnelly et al., 2005; Lambert et al., 2014). This article will, 
therefore, focus on hepatocyte isolation, followed by quantification of β-fatty acid 
oxidation and de novo lipogenesis. 
  Numerous methodologies have been developed to interrogate hepatocyte lipid 
metabolism. Though it is possible to measure metabolism of fat in vivo using 
stable isotopes (Befroy et al., 2014; Parks and Hellerstein, 2006), these methods 
are costly, and require large numbers of animals. Additionally, the ability to 
investigate the effect of exogenous chemicals is limited due to the nature of in 
vivo experimentation. In contrast, the isolation of primary hepatocytes from 
mouse liver provides an affordable avenue to pursue (Goncalves et al., 2007). 
Furthermore, studying hepatocytes in culture allows investigators to study the 
effects of varying chemicals on lipid processing while circumventing the 
difficulties of in vivo experimentation. Finally, isolated hepatocytes avoid any 
confounding from varying genetics since they are derived from the liver of a 
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single animal. 
  Here we isolate and culture of hepatocytes, and we measure β-fatty acid 
oxidation and de novo lipogenesis, using radiolabeled palmitate. The protocol 
detailed below is straight forward, effective, and reproducible. 
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Protocol 
 
All animal experimentation should be carried out in accordance with local and 
federal regulations and with the approval of an institutional IACUC and radiation 
safety administration. 
 
1. Preparation 
1.1) Several days prior to the assay, thaw the 500mL bottle of Liver Digest 
Medium (LDM) and refreeze ~35mL aliquots in50 mL conical tubes. Store at -20 
°C until needed.  
1.2) One day prior to the assay, pre-sterilize clean dissection tools by autoclave. 
1.3) On the day of the assay, treat the necessary amount of 24-well culture 
plates with collagen. 
1.3.1) Mix 1 part of 3 mg/mL rat tail collagen with 50 parts of PBS. Add 
approximately 500 μL to each well of a 24-well plate and incubate for 3-5 minutes 
at room temperature (RT). Remove the collagen and allow plate to air dry in 
hood. Repeat at least one additional time.  
Note: Collagen coating can be performed up to one week in advance and plates 
stored at 4 °C sealed in plastic wrap. 
1.4) Prepare LDM for assay: Thaw LDM and warm to 37 °C and adjust pH to 7.4 
using 1 N KOH. Filter using 0.2 μm syringe filter and place in a recirculating 42 
°C water bath. 
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1.5) Warm 25 mL of Liver Perfusion Medium to 42 °C in recirculating water bath 
1.6) Prepare 90% colloidal silica coated with polyvinylpyrrolidone solution: Add 1 
mL of 10x DPBS to 9 mL of colloidal silica coated with polyvinylpyrrolidone. 
Adjust pH to 7.4 using 0.1 N HCl. Filter with a sterile 0.2 μm syringe filter. Store 
at RT. 
1.7) Warm Plating Medium to 37 °C. 
 
2. Isolation of Primary Mouse Hepatocytes 
2.1) Set up peristaltic pump, tubing, and dissection table: Sterilize tubing by 
flushing with 5mL 70% ethanol in distilled water, followed by 10mL of sterile 
water. Place tubing in Liver Perfusion Medium and run pump to fill entire length 
of tubing. 
2.2) Sacrifice mouse by the institutionally approved method 
2.3) Dissect open the abdominal cavity:  Spray the mouse abdomen liberally with 
70% ethanol. Using blunt-end scissors, make a midline incision through the 
dermis the length of the abdomen and reflect laterally. Make a similar incision in 
the peritoneum to expose the viscera. Using a blunt instrument, gently displace 
the intestines to expose the abdominal vasculature Locate the abdominal inferior 
vena cava (IVC) and place a suture underneath the blood vessel, distal to the 
renal vein 
2.4) Distal to the suture, place a needle and catheter into the IVC, advancing it 
beyond the level of the suture. With the needle still in place, tie the suture around 
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the catheter to hold it in place. Carefully remove the needle. If done correctly, 
blood with flow through the catheter. 
2.5) Using a pipet, fill the remaining area in the catheter with perfusion medium, 
ensuring that no air is present. With great care, attach the tubing to the catheter. 
2.6) Dissect open the lung cavity: gently reflect the superior liver lobes to expose 
the diaphragm. Carefully puncture the diaphragm, then make a lateral incision to 
expose the pleural cavity, taking care to avoid the gall bladder and pleural 
vasculature. Place a bulldog clamp around the thoracic inferior vena cava just 
proximal to the hepatic vein. 
2.7) Cut the portal vein and turn on the pump at 3-4 mL / min. Perfuse the liver 
with Liver Perfusion Medium for 5 minutes using approximately 20mL of 
perfusion medium.  
Note: The liver should immediately change from red to grey/tan. If portions of the 
liver remain red, this likely indicates poor perfusion, and the likelihood of 
successful isolation is greatly diminished. During the perfusion, be careful to 
ensure the medium does not run out and that no bubbles enter the tubing. 
2.8) Following the 5 minute incubation, stop the pump and transfer the tubing to 
Liver Digest Medium. Restart the pump and perfuse the liver for another 10-15 
minutes (until the medium is exhausted).  
2.9) At the end of the perfusion, stop the pump. The liver should have a pinkish 
hue and appear somewhat enlarged. Excise the liver by careful dissection. 
Remove the gall bladder and transfer the liver to 10 cm tissue culture dish. 
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2.10) In a biosafety cabinet, add 10 mL of Plating Medium (Table 2.1) to the liver. 
Gently scrape the liver using either forceps or a scalpel to remove the 
hepatocytes. Filter the suspension using a 100 μm cell strainer and transfer to a 
50 mL conical tube. Wash the plate with an additional 10 mL of Plating Medium 
and pool in the 50mL conical tube. 
2.11) Pellet the cells by centrifuging for 5 minutes at 350 x g, 4 °C. 
2.12) Aspirate medium and resuspend pellet in 10 mL of Plating Medium and add 
10 mL of 90% colloidal silica coated with polyvinylpyrrolidone. Mix gently and 
centrifuge as in step 2.11. After centrifugation, a layer of dead cells will be 
floating on the top of the mixture, while the live cells will pellet to the bottom. 
2.13) Aspirate dead cells and medium. Wash 2 times with 20 mL of Plating 
Medium, centrifuge as in 2.11. 
2.14) Resuspend cells in 10 mL of Plating Medium. Count cells with a 
hemocytometer and place 9 x 104 cells/well in collagen-treated 24-well culture 
dishes. Incubate in a 37 °C tissue culture incubator for 2 hours. Each plate can 
be used for either the Fatty Acid Oxidation assay OR the Lipogenesis assay.  
2.15) Optionally, change wells to Maintenance Medium (Table 1) and culture at 
37 °C. Cells can be cultured for 2-3 days without affecting assay results.  
  
42 
 
 
Table 2.1 Culture Media 
  
    
Plating Medium 
    
DMEM 500 mL 
FBS 10 % 
Sodium pyruvate 2mM 
Pen/Strep 2 % 
Dexamethasone 1 μM 
Insulin 0.1 μM 
    
Maintenance Medium 
    
DMEM 500 mL 
BSA Fraction V 0.2 % 
Sodium pyruvate 2 mM 
Pen/Strep 2 % 
Dexamethasone 0.1 μM 
Insulin 1 nM 
    
Serum Starvation Medium 
    
DMEM 500 mL 
BSA Fraction V 0.2 % 
Sodium pyruvate 2 mM 
Pen/Strep 2 % 
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3. Fatty Acid Oxidation Assay 
[Warning: Use of radioactivity can be hazardous. All purchasing, storage, 
handling, and disposal of radioactive material should be carried out in 
accordance with institutional, state, and federal regulations and guidelines.] 
3.1) 16-20 hours prior to assay, wash cells 2 times with warm PBS. Change the 
cells to serum-free Serum Starvation Medium (Table 1) with 20 nM glucagon and 
incubate overnight at 37 °C. (Note: Because fetal bovine serum contains an 
unknown concentration of metabolic hormones (e.g. insulin, glucagon), it is 
necessary to serum starve the cells to remove any confounding effects this may 
have on the assay. Cells are viable in Serum Starvation Medium for >24 hours. 
Glucagon treatment is used to stimulate fatty acid oxidation within the 
hepatocytes. 
3.2) On the morning of the assay, prepare Pre-Incubation Medium: Resuspend 
an appropriate amount of Sodium Palmitate in ultrapure water to make a 100 mM 
solution and heat to 70 °C for 10 minutes. In the meantime, prepare the requisite 
amount (0.5 mL per well of a 24-well plate) of DMEM with 25 mM HEPES, 1% 
BSA Fraction V, and 20 nM glucagon. Heat to 37 °C.  
3.2.1) Once solubilized, add Palmitate to a final concentration of 250 μM to the 
medium. Change hepatocytes to Pre-Incubation Medium and incubate at 37 °C 
for 2 hours. Reserve some Pre-Incubation Medium at 37 °C for later use. 
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3.3) During the incubation, dry an appropriate amount of 14C-Palmitate (0.5 
μCi/well) by evaporation under nitrogen gas.  
3.3.1) For example, to measure 24 samples in a 24-well plate, transfer 120 μL of 
0.1 μCi/mL14 C-Palmitate to a 1.5 mL tube. Slowly evaporate the ethanol solvent 
by blowing nitrogen gas over the solution from a distance of 3-5 cm in a fume 
hood. The solvent should evaporate in approximately 30-40 minutes, leaving dry 
14C-Palmitate in the bottom of the tube. 
3.4) Approximately fifteen minutes before the end of the incubation, resuspend 
the 14C-Palmitate in 0.1 N NaOH (12.5 μL/μCi). Incubate at 70 °C for 10 minutes. 
Add three volumes of warm Pre-Incubation Medium and mix by pipetting up and 
down. 
3.5) Spike each well with 25 μL of diluted 14C-Palmitate. Mix by gently rocking the 
plate and incubate at 37 °C for 90 minutes. This is the Assay Plate. 
3.6) During the incubation, prepare the Filter Paper Plate (Fig. 2.1): cut 2 cm x 2 
cm squares of filter paper and place one at the bottom of each well in a fresh 24-
well dish. Cover the top of the dish tightly with parafilm. Carefully rub the 
circumference of each well with the edge of pipet tip box to cut an opening in the 
parafilm over each well. Remove the excised circle of parafilm. 
3.7) Ten minutes before the end of the incubation, add 200 μL of 3 N NaOH to 
each well of the Filter Paper Plate, making sure the filter paper absorbs all of the 
liquid. 
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Figure 2.1 Preparation of the filter plate. To prepare the filter plate as 
described in Step 3.6, remove the cover from a sterile 24-well plate. Place a 2x2 
cm piece of filter paper at the base of each well. Overlay the entire plate with a 
7x4”piece of parafilm, and rub the plate to tightly seal the top of the wells. This 
will generate perforated circles of parafilm over the well openings, which should 
be removed. After addition of the perchloric acid in Step 3.9, place the Filter 
Paper Plate tightly over the Assay Plate to produce a seal. 
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(Optional 3.7.1: Prior to freezing, transfer the medium to a fresh 24-well plate. 
After washing once with PBS, the remaining cells can be lysed in 0.1N HCl and 
protein content calculated by BCA assay) 
3.8) At the end of the incubation, snap-freeze the Assay Plate in liquid nitrogen. 
Be careful to ensure each well is completely frozen before proceeding.  
3.9) Add 100 μL of 70% Perchloric Acid to each well of the Assay Plate. 
Immediately cover with the Filter Paper Plate. Place the plates on an orbital 
shaker and rock at orbital speed of 80 rpm at room temperature for 2 hours. 
3.10) Following the incubation, process the samples:  
3.10.1) To measure the CO2 fraction, transfer the filter paper squares to 4mL 
liquid scintillation fluid in a scintillation vial and measure 14C signal. 
3.10.2) To measure the acid soluble material, transfer 400 μL of medium to a 1.5 
mL microfuge tube. Centrifuge at maximum speed for 10 minutes. Add 100 μL of 
the resulting supernatant to 500 μL of 2:1 Chloroform-Methanol (v/v), and vortex 
briefly. Add 250 μL of water to the mixture, and vortex again. Centrifuge samples 
for 10 minutes at 3000 x g. Transfer 200 μL of the upper phase to 4mL liquid 
scintillation fluid in a scintillation vial and measure 14C signal. 
 
4. Lipogenesis Assay 
4.1) The evening prior to beginning the assay, wash the cells 2 times with warm 
PBS. Change the hepatocytes to Serum Starvation Medium with 100 nM insulin. 
Incubate overnight at 37 °C. (Note: Because fetal bovine serum contains an 
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unknown concentration of metabolic hormones (e.g. insulin, glucagon), it is 
necessary to serum starve the cells to remove any confounding effects this may 
have on the assay. Cells are viable in Serum Starvation Medium for >24 hours. 
Insulin is used in this assay to stimulate lipogenesis.) 
4.2) Make Lipogenesis Medium: Serum Starvation Medium with 100 nM insulin, 
10 μM cold acetate and 0.5 μCi 3H-Acetate / well. Change cells to Lipogenesis 
Medium and incubate at 37 °C for 2 hours. Include any compounds of interest to 
be tested. 
4.3) After the incubation period, wash cells 2 times with PBS. Lyse cells by 
scraping in 120 μL of 0.1 N HCl. Reserve 10 μL for protein assay (assess by 
BCA assay), and transfer 100 μL to 1.5 mL microfuge tube. 
4.4) Extract lipids by addition of 500 μL of 2:1 chloroform-methanol (v/v). Vortex 
briefly and incubate at RT for 5 minutes. Add 250 μL of water, vortex and 
incubate at RT for an additional 5 minutes. Centrifuge samples 10 minutes at 
3000 x g, RT. Carefully transfer lower phase to 4mL liquid scintillation fluid in a 
scintillation vial and measure 3H activity. 
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Representative Results 
 
Hepatocyte isolations typically result in 1-3 x 107 total cells. After overnight 
incubation, the cells will appear hexagonal, many of which will be binucleated 
(Fig. 2.2). Healthy cells should be devoid of granulations or blebs, which are 
indicative of cell death. 
In general, Fatty Acid Oxidation assay is run in three to four replicates per test 
compound. Counts for the CO2 samples are approximately one-fifth of those 
derived from the acid soluble material. We typically calculate the ratio of CO2 to 
acid soluble material as a measure of complete oxidation (that is, the amount 
oxidized via the citric acid cycle). Substances that promote cellular respiration, 
such as Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) will shift 
this ratio toward CO2, indicating more oxidation via the TCA cycle. Inhibitors of 
the respiratory chain will diminish oxidation on the whole (Fig. 2.3). When piloting 
this assay, it is best to include a no-cell control to verify the procedure is 
producing cell-specific activity. 
 
The Lipogenesis Assay is most often compared to a zero timepoint control (cells 
treated with substrate immediately before harvesting). The assay should be 
linear versus time through at least four hours of incubation. Compounds which 
enhance fatty acid oxidation, such as FCCP, or diminish ATP synthesis, such as 
oligomycin, will reduce lipogenic activity (Fig. 2.4).  
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Figure 2.2 Primary hepatocytes in culture. Phase contrast images of healthy 
and unhealthy primary mouse hepatocytes 16 hours after plating in collagen 
coated 24-well plates. Scale bar, 200 μm. 
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Figure 2.3 Fatty acid oxidation by primary mouse hepatocytes in culture. 
14C-Palmitate oxidation to (A) CO2, (B) acid soluble material, and (C) the ratio of 
CO2 to acid soluble material from primary hepatocytes incubated with vehicle, 
FCCP, or oligomycin. Data are mean ± SEM. *p<0.05, **p<0.01 vs. vehicle by 
one-tailed Student’s t-test. 
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Figure 2.4 Lipogenesis in Cultured Primary Mouse Hepatocytes.                
(A) Lipogenic activity vs. time in primary hepatocytes treated with 3H-acetate and 
(B) lipogenic activity in the presence of vehicle, oligomycin, or FCCP. Data are 
mean ± SEM. ***p<0.001 vs. vehicle by one-tailed Student’s t-test. 
 
  
52 
Discussion 
 
  The time from sacrifice to perfusion should be less than 3 minutes for ideal 
perfusion and collagenase digestion of the liver. Once perfusion with Perfusion 
Medium is initiated, the liver should immediately change appearance to from red 
to pale. After approximately 10 minutes of incubation with LDM, the liver will 
appear swollen and pink. In the event that perfusion is insufficient, the liver may 
not exhibit these changes, and this will typically result in a lower hepatocyte yield. 
  Following the washing steps, isolated hepatocytes can be stored for several 
hours in suspension on ice prior to plating. Once plated, cultured hepatocytes 
require several hours to adhere and spread out. Following 2 hours of incubation 
in Plating Medium, the hepatocytes will remain small and round. After an 
overnight incubation, hepatocytes will take on a more characteristic hexagonal 
appearance, many of which will be binucleated. If the preparation is unhealthy, 
the cells will exhibit numerous granulations and occasional blebbing, indicative of 
cell death. In order to best maintain culture viability, media should be changed 
every 24 hours and care taken to minimize exposure to open air. 
  Sodium palmitate is insoluble in water at room temperature, however, after 
incubation at 70 °C it should completely dissolve. Exposure to room temperature 
will cause the lipid to solidify rapidly, thus it is imperative to work quickly. Once 
palmitate has been dissolved in Pre-Incubation Medium, it is critical to maintain 
the medium at 37 °C in order to maintain solubility of the lipids.  
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  As mentioned above, to ensure accurate results from the Fatty Acid Oxidation 
assay, the medium must be completely frozen in liquid nitrogen. This prevents 
any escape of CO2 during the addition of perchloric acid to the wells. Immediately 
following the addition of the perchloric acid to the frozen samples, the assay plate 
must be tightly covered by the Filter Paper Plate, making sure to align the plates 
for gas transfer between the wells. Since the filter paper is soaked with an 
excess of NaOH, the stoichiometry of the reaction is capable of capturing the 
released CO2 as NaHCO3. Experiments following this protocol have generated 
reproducible results, with typical replicates having %CV ≤ 10. If needed, acid 
soluble material from the Fatty Acid Oxidation assay or the cell lysate from the 
Lipogenesis assay are capable of being stored at -80 °C and processed later 
without any appreciable effect on results. The assays described above allow for a 
relatively simple and time efficient mechanism to assess lipid metabolism in 
primary hepatocytes isolated from mouse liver. Through use of ex vivo culture, 
these methods allow testing the effects of several conditions on fatty acid 
oxidation and lipogenesis. This protocol may be adapted to assess the role of 
genetic alterations on these processes, however, the isolation of hepatocytes is 
time-limiting and thus in vivo analyses may be more suitable for investigating 
certain transgenic animal models. If analysis of multiple hepatocyte preparations 
is necessary, normalization of assay values to protein levels can be performed as 
described in the optional step 3.7.1 and used for normalization. We recommend 
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assays performed in multiple preparations be compared as relative changes 
versus a suitable control.  
  Finally, we have not explored the option of longer culture periods, however, 
hepatocytes may exhibit equivalent metabolic characteristics after several days 
in culture. With slight modification, this protocol may be adapted to allow for 
several day treatments prior to assessing the effects of compounds on lipid 
metabolism. 
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CHAPTER III: OXPHOS-MEDIATED INDUCTION OF NAD+ PROMOTES 
COMPLETE OXIDATION OF FATTY ACIDS AND INTERDICTS NON-
ALCOHOLIC FATTY LIVER DISEASE 
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Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming one of the 
leading causes of liver disease in Western societies (Bellentani et al., 2010). 
NAFLD spans a spectrum of disease. In simple steatosis, there is benign 
accumulation of hepatic lipid (Angulo, 2002). In steatohepatitis, inflammation and 
attendant hepatocyte injury occur, which together may progress to fibrosis or, on 
rare occasion, hepatocellular carcinoma (Adams et al., 2005; White et al., 2012). 
Worldwide, the prevalence of fatty liver disease is 10-30% (Bellentani et al., 
2000; Browning et al., 2004). Obesity and diabetes constitute key factors in its 
development. Recent work has demonstrated that, in NAFLD, hepatic insulin 
resistance exacerbates whole body insulin resistance (Michael et al., 2000). 
Efforts to mitigate NAFLD are, thus, anticipated to improve not only fatty liver 
disease but also mitigate whole body insulin resistance and diabetes. Central to 
this goal is deciphering the key pathways that influence non-alcoholic fatty liver. 
Defective mitochondrial oxidative phosphorylation (OXPHOS) features 
prominently in NAFLD. There is a striking negative association between 
OXPHOS and NAFLD. Notably, OXPHOS activity is decreased in patients with 
non-alcoholic fatty liver disease (Cortez-Pinto et al., 1999; Perez-Carreras et al., 
2003). Functional changes are supported by energetically unfavorable 
perturbations in mitochondrial cristae, which are the structural underpinning of 
OXPHOS (Caldwell et al., 1999; Sanyal et al., 2001). These changes are 
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accompanied by both activation of protein kinase C epsilon (PKCε) via increased 
diacylglycerol (DAG) and an increase in mitochondrial reactive oxygen species 
(ROS) (Kumashiro et al., 2011; Seki et al., 2002). Both pathways have been 
implicated in hepatic insulin resistance, and thus, proposed as important 
mediators of hepatic insulin resistance in NAFLD. Additionally, fatty liver 
associates with reductions in OXPHOS-dependent [NAD+]/[NADH], which 
allosterically regulates complete oxidation of fatty acids via the citric acid cycle 
(Kendrick et al., 2011; Kim et al., 2011). Due to a number of confounding 
variables, a causal role for defective OXPHOS in NAFLD and putative underlying 
mechanisms remains obscure. Hitherto, efforts to increase OXPHOS in liver 
have been thwarted by a lack of genetic (or pharmacological) tools that 
specifically augment hepatic OXPHOS in vivo. Hence, the precise role of 
augmented OXPHOS in NAFLD remains an open question. 
Here we activate OXPHOS in liver and show that it interdicts NAFLD and 
mitigates whole body insulin resistance. We increased OXPHOS in mouse liver 
by ectopically expressing leucine-rich pentatricopeptide repeat containing 
(LRPPRC; but also called LRP130). LRPPRC is a 130 kD protein that is 
defective in Leigh Syndrome French Canadian variant, a rare form of the 
mitochondrial disorder Leigh Syndrome (Mootha et al., 2003a). In both gain- and 
loss-of-function models, LRPRPC regulates mitochondrially encoded gene 
expression, which in turn regulates the expression of 13 polypeptides central to 
the formation of mature OXPHOS complexes (Cooper et al., 2006; Gohil et al., 
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2010; Liu et al., 2014; Liu et al., 2011; Mourier et al., 2014; Ruzzenente et al., 
2012; Sondheimer et al., 2010). LRPPRC is reported to regulate mitochondrially 
encoded gene expression by increasing mitochondrial transcription (Liu et al., 
2014; Liu et al., 2011; Sondheimer et al., 2010) as well as stabilizing some 
mitochondrially encoded transcripts (Ruzzenente et al., 2012; Sasarman et al., 
2010). Because an increase in mitochondrially encoded subunits is sufficient to 
drive mature OXPHOS complexes, ectopic expression of LRPPRC increases 
mitochondrial OXPHOS and oxygen consumption (Liu et al., 2014; Liu et al., 
2011). Using mice with transgenic expression of LRPPRC in liver, we show 
enhanced hepatic OXPHOS protects against fatty liver and reduces liver 
inflammation in the setting of diet-induced obesity. Additionally, hepatic and 
whole-body insulin sensitivity were increased, changes possibly explained by 
reduced reactive oxygen species and diminished PKCε activation. Mice with 
enhanced hepatic OXPHOS have a dramatic increase in the ratio of 
[NAD+]/[NADH], which promotes complete lipid oxidation in hepatocytes. Using 
pharmacological activators and inhibitors of cellular respiration, we demonstrate 
that respiratory capacity dictates [NAD+]/[NADH] in hepatocytes. Moreover, 
increasing the concentration of NAD+ in hepatocytes promotes complete fatty 
acid oxidation, and rescues impaired fatty acid oxidation in hepatocytes deficient 
for either OXPHOS or SIRTUIN 3 (SIRT3). Taken together, these data suggest 
that augmented hepatic OXPHOS enhances NAD+, which in turn promotes 
complete fatty acid oxidation and interdicts NAFLD.  
60 
Materials and Methods 
 
Animal Model 
  Liver-specific Lrpprc transgenic mice were created as described previously (Liu 
et al., 2011). Liver-specific expression was driven by a transthyretin enhancer 
and promoter.  These mice were backcrossed to a C57BL/6 background for at 
least 6 generations. Wild-type littermate control mice were used to make 
comparisons. Mice were housed in a facility with 12h light/12h dark cycle.  For 
high-fat diet feeding, male mice aged 7 weeks were fed a 55% kcal from fat diet 
(Harlan Teklad TD-93075) for 12 weeks before metabolic phenotyping. Following 
the designated high-fat feeding period, mice were sacrificed by CO2 euthanasia 
and tissues embedded for histology or flash-frozen in liquid nitrogen for further 
analysis. All animal experiments were approved by the IACUC of the University 
of Massachusetts Medical School (Protocol #A-2085-12). 
 
Pathological Assessment of Liver 
  Hepatic steatosis and inflammation in liver sections was assessed by an 
unbiased pathologist as previously described (Kleiner et al., 2005). Briefly, 
steatosis was graded as Healthy (<5% of liver involvement), Mild (5-33%), 
Moderate (34-66%) or Severe (>66%), and inflammation as Healthy (no 
inflammation), Mild (1-2 foci per 10X field), Moderate (2-4 foci), or Severe (>4 
foci). 
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Metabolic Cage Analysis 
  Analysis of energy expenditure, activity, and food intake was performed by the 
University of Massachusetts Mouse Metabolic Phenotyping Core using metabolic 
cages (TSE Systems). 
 
Protein and Gene Expression 
  Whole tissue lysates were harvested by homogenization in a TissueLyzer 
(Qiagen) using lysis buffer (50mM Tris pH 7.5, 0.15mM NaCl, 1% NP-40, 0.25% 
sodium deoxycholate, 1mM EDTA) including a protease inhibitor cocktail (Sigma) 
and separated by SDS-PAGE (Invitrogen). Samples were transferred to a PVDF 
membrane and blocked in 5% BSA solution for 1 hour, then incubated with 
primary antibody overnight at 4 °C.  Membranes were washed three times with 
tris-buffered saline (50mM Tris, 150mM NaCl, 0.1% Tween-20, pH 7.6) then 
probed with the appropriate secondary antibody for 1 hour at room temperature. 
Following secondary incubation, samples were washed as above and proteins 
detected using ECL (GE Healthcare). Antibodies to LRPPRC were generated as 
previously described (Liu et al., 2011).  Antibodies for Myc , Actin (Santa Cruz), 
COX1, Citrate Synthase, VDAC (MitoSciences), phospho-AKT, AKT (Cell 
Signaling) were purchased and diluted according to the manufacturer 
instructions. Densitometric analysis was performed using ImageStudio (Licor) by 
comparison to a reference protein (actin). RNA samples were harvested from 
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tissue in Trizol (Invitrogen) and analyzed as described previously (Liu et al., 
2011).   
 
Mitochondrial Respiration, Complex Activity, and Isolation of Primary 
Hepatocytes 
  Mitochondria were harvested from chow-fed WT and Tg/Tg mouse livers and 
oxygen consumption in the presence of pyruvate and malate measured on a 
Clarke-type electrode (Hansatech) as previously described (Frezza et al., 2007) 
using 0.5 mg of mitochondrial protein. All mitochondria used had an RCR > 3.0 
and membrane integrity > 80%. Individual respiratory complex activity was 
performed as previously described (Liu et al., 2011). Primary hepatocytes from 
WT and Lrpprc transgenic mice were isolated by perfusion and collagenase 
treatment as previously described (Goncalves et al., 2007). 
 
Measurement of Liver and Serum Triglycerides 
  Triglyceride levels in serum and liver from mice fasted for 16 hours were 
measured by PicoProbe fluorometric assay (BioVision) according to the 
manufacturer’s specifications.  For liver, ~10 mg of tissue was homogenized in 
5% Triton X-100 in water using a TissueLyzer (Qiagen) then boiled twice for 5 
minutes to solubilize lipids. Samples were spun 13,000 x g for 5 minutes to pellet 
insoluble materials, then assayed using the provided materials. Values were 
normalized to protein concentration as measured by BCA assay (Thermo). 
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Glucose and Insulin Tolerance Testing 
  Glucose tolerance testing was performed after an overnight fast by 
intraperitoneal injection of 1.5 mg/g dextrose. Blood glucose content was 
analyzed at 15, 30, 60, 90, and 120 minutes by tail vein sampling.  For insulin 
tolerance, mice were fasted 6 hours, then injected with 0.75mU/g human insulin 
and monitored similarly.  Blood glucose levels were determined using a 
OneTouch Ultra monitor and strips (LifeScan). 
 
Determination of Mitochondrial Superoxide, Proton Gradient, and PKCε Activity 
  We used MitoSox Red (Invitrogen) per manufacturer protocol to measure 
mitochondrial superoxide in human hepatoma (HepG2) cells stably expressing 
ectopic human Lrpprc. Mitochondrial membrane potential was determined in cells 
plated in a 96-well dish by staining with 1µg/mL JC-1 dye (Life Technologies) for 
20 minutes at 37˚C per manufacturer instructions.  
  Cytosolic and membrane-bound PKCε was determined by fractionation and 
immunoblotting as previously described (Qu et al., 1999). The presence of PKCε 
was determined by immunoblot and activity calculated using the ratio of 
membrane to cytosolic signal as determined by densitometry. 
 
Nicotinamide Treatment and [NAD+]/[NADH] Measurement 
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  Primary hepatocytes were incubated for 16 hours in serum-free medium in the 
presence or absence of nicotinamide (NAM) at the doses indicated. For inhibitor 
experiments, cells were incubated for 2 hours in the presence of 4 μM Carbonyl 
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) or 1 µM rotenone. 
Measurement of NAD+ and NADH was performed using the EnzyFluo 
[NAD+]/[NADH] kit (BioAssays) per the manufacturer’s instructions.  
 
Fatty Acid Oxidation Assay 
  The oxidation of palmitate was measured in primary hepatocytes as previously 
described with minor modifications (Liu et al., 2011). Briefly, primary hepatocytes 
were incubated in serum-free medium containing 20nM glucagon ± NAM for 16 
hours. Following this incubation, medium was changed to DMEM with 1% BSA 
Fraction V, 20 mM HEPES, and 250 μM cold palmitate. Following incubation at 
37 °C for 2 hours, wells were spiked 14C-palmitic acid and incubated for an 
additional 90 minutes. Complete oxidation of palmitate was measured by the 
release of 14C-carbon dioxide after addition of perchloric acid (10% v/v final 
concentration). Chemical manipulation of the electron transport chain was 
accomplished by treatment with either 4 μM FCCP or 1 μM rotenone 30 minutes 
prior to the addition of radiolabeled substrate. 
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Statistics 
  Statistical analyses were performed using GraphPad (Prism) or SAS/STAT. 
Differences in protein densitometry, cellular respiration, relative mtDNA levels, 
area-under-the-curve for glucose and insulin tolerance tests, triglyceride levels, 
and mitochondrial membrane potential were compared by two-tailed, unpaired 
Student’s t-test. Membrane-bound and membrane-to-cytosol ratios of PKCε were 
compared using a one-tailed, unpaired Student’s t-test. Gene expression was 
analyzed by either two-tailed, unpaired Student’s t-test (nuclear encoded 
transcription factors) or by two-way ANOVA using Bonferroni’s posttest. 
Comparison of maximal respiration to LRPPRC protein levels was performed 
using linear regression. Steatosis and inflammation grading was assessed by 
chi-square analysis. For determination of differences in mouse weight curves, a 
mixed model with Bonferroni correction was performed. In general, P values less 
than 0.05 were considered significant. 
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Results 
 
Ectopic expression of liver-specific LRPPRC promotes hepatic OXPHOS 
  In order to assess the role of OXPHOS in the progression of NAFLD in vivo, we 
ectopically expressed Lrpprc (also called Lrp130) in a liver-specific manner. As 
shown in Figure 3.1a and 3.1b, there is a dose-dependent increase of LRPPRC 
protein in liver harvested from hemizygous (Tg/0) and double-hemizygous 
transgenic mice (Tg/Tg). Gene expression for Lrpprc matched LRPPRC protein 
levels (Fig. 3.1e and Fig. 3.S1). Importantly, ectopic expression of LRPPRC 
protein was not observed in other tissues, supporting liver-specific expression 
(Fig. 3.1c). Because double transgenic mice had the greatest expression of 
LRPPRC protein, and we sought to maximize our model of hepatic OXPHOS, 
double hemizygous mice became the major focus of our studies, while 
hemizygous mice were used in select experiments. Throughout our studies, the 
phenotype of hemizygous mice was intermediate between wild-type littermate 
control mice and double hemizygous transgenic mice. Consistent with prior 
reports, ectopically expressed LRPPRC resulted in increased mitochondrially 
encoded gene expression (Fig. 3.1f and Fig. 3.S1). Additionally, protein analysis 
in primary hepatocytes isolated from Tg/Tg mice showed greater COX1 protein 
levels compared with WT mice (Fig. 3.1d). We did not observe changes in 
several markers of mitochondrial content – mRNA expression of Polrmt, Tfam,  
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Figure 3.1 LRPPRC promotes mitochondrially encoded gene expression in 
liver. (A) Protein expression and (B) quantification in livers of wild-type littermate 
controls (WT), hemizygous (Tg/0), and double hemizygous (Tg/Tg) LRPPRC 
transgenic mice. (C) Protein expression in heart, spleen, brown adipose tissue 
(BAT) and liver in WT and Tg/Tg mice. (D) Protein expression in WT and Tg/Tg 
cultured primary hepatocytes. (E) Nuclear Lrpprc, mitochondrial polymerase 
(Polrmt), mitochondrial transcription factor A (Tfam), and mitochondrial 
transcription factor B2 (Tfb2m) and (F) mitochondrially encoded respiratory 
complex subunit gene expression in Tg/Tg and control livers. (G) Genetic 
determination of mitochondrially encoded DNA content in the samples. For all 
experiments, n = 3 or 4. Data are mean ± SEM * p<0.05, ** p<0.01, *** p<0.001 
vs. WT by two-tailed unpaired Student’s t-test (B, E, G) or 2-way ANOVA with 
Bonferroni’s post-test (F). 
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and Tfb2m (Fig. 3.1e), protein expression of citrate synthase or VDAC (Fig. 
3.1a), or mtDNA copy number (Fig. 3.1g), suggesting augmentation of OXPHOS 
was not due to increased mitochondrial mass. 
  Next, we tested if ectopic expression of hepatic LRPPRC could augment 
OXPHOS in mouse liver mitochondria. Using mitochondria isolated from livers of 
chow fed wild-type littermate control mice and Tg/Tg mice, we measured oxygen 
consumption using a Clarke-type electrode (Fig. 3.2a). While basal (state II and 
IV) respiration was unchanged in transgenic mitochondria, ADP-stimulated 
respiration (state III) was increased (Fig. 3.2b and 3.2c). Furthermore, the level 
of LRPPRC protein predicted maximal oxygen consumption (FCCP) in both WT 
and Tg/Tg mitochondria (r2=0.948, p=0.001), indicating that respiratory capacity 
directly correlates with LRPPRC protein expression (Fig. 3.2d). Compared with 
WT mitochondria, Tg/Tg mitochondria had equivalent levels of proton leak 
(27.6% vs. 24.5% respectively, p>0.05), indicating that the increase in oxygen 
consumption was attributable to bona fide OXPHOS. These functional 
measurements are in agreement with observed increases in complex I, III, IV and 
V activities for cells replete with LRPPRC (Fig. 3.S2).  
  Increased oxygen consumption could result from enhanced efficiency of 
OXPHOS or an increase in the number of OXPHOS units per mitochondrion, that 
is, cristae density. As shown in Figure 3.2e, the P:O ratio (that is, the ratio of 
ATP molecules generated per molecule of oxygen consumed in state III) was 
unaltered in transgenic mitochondria, indicating increased OXPHOS units per   
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Figure 3.2 Liver-specific LRPPRC augments hepatic OXPHOS. (A) 
Representative plot, (B) absolute and (C) relative changes in oxygen 
consumption rate (OCR) in isolated mitochondria from WT and LRPPRC Tg/Tg 
livers measured on a Clarke-type electrode. (D) FCCP induced maximal OCR vs. 
LRPPRC protein levels in isolated mitochondria from WT and Tg/Tg livers. (E) 
P:O ratio calculated from Clarke-electrode data. For all experiments, n = 3 or 4. 
Data are mean ± SEM (B—E), * p<0.05, ** p<0.01, *** p<0.001 by two-tailed 
unpaired Student’s t-test (B, C) or linear regression (D). 
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mitochondrion. While we did not measure cristae density in this study, these data 
are consistent with previous reports by our group and others demonstrating a 
role for LRPPRC in regulating mitochondrial cristae density (Liu et al., 2011; 
Mourier et al., 2014). In summary, ectopic expression of LRPPRC in the liver 
augments hepatic OXPHOS without gross alterations in mitochondrial mass.  
 
Augmented hepatic OXPHOS improves whole body insulin sensitivity 
  The liver plays an important role in regulating whole body metabolic 
homeostasis. Therefore, we characterized the effect of enhanced hepatic 
OXPHOS on whole-body energy balance and insulin sensitivity. In order to 
determine the role of increased hepatic OXPHOS in NAFLD, we induced fatty 
liver by feeding mice a high-fat diet (HFD; 55% kcal fat) for 12 weeks. Expression 
of Lrpprc and mitochondrially encoded OXPHOS genes remained elevated in 
Tg/Tg mice following high-fat feeding (Fig. 3.S3). As shown in Figures 3.3a and 
3.3b, mice with augmented hepatic OXPHOS had improved insulin sensitivity as 
assessed by ITT and GTT. Improvement in insulin sensitivity was dependent on 
the dose of LRPPRC, since double transgenic were more insulin sensitive than 
single transgenic liver-specific LRPPRC mice.  Alterations in insulin sensitivity 
can be due to a multitude of factors, thus we evaluated processes that might 
explain this finding. Though weight gain was similar between all groups  
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Figure 3.3 Hepatic OXPHOS enhances whole body glucose homeostasis. 
(A) Glucose and (B) insulin tolerance tests and area-under-the-curve (insets) and 
(C) weights in wild-type littermate control mice (WT), LRPPRC single 
hemizygous (Tg/0), and double hemizygous (Tg/Tg) mice fed a high-fat diet for 
12 weeks, n = 10. (D) Hourly activity, (E) daily food intake, and (F) diurnal energy 
expenditure (7AM—7PM) in WT and Tg/Tg mice fed a high-fat diet > 20 weeks n 
= 3–6. (G) ER stress and (H) antioxidant gene expression in high-fat fed WT and 
Tg/Tg mouse liver, n = 9 or 10. (I) Mitochondrial superoxide production and (J) 
mitochondrial membrane potential (ΔΨm) in HepG2 cells ectopically expressing 
LacZ (control) or LRPPRC n = 24. (K) Immunoblot and quantification of phospho-
AKT in cultured primary hepatocytes from chow-fed WT and Tg/Tg mice treated 
with 25nM insulin, n = 3. (L) Immunoblot and (M) quantification of membrane or 
(N) membrane: cytosolic PKCε in high-fat fed WT and Tg/Tg mouse livers, n = 5 
or 6. Data are mean ± SEM, *p<0.05, **p<0.01, ***p<0.001 vs. WT by two-way 
ANOVA (A, B), two-tailed unpaired Student’s t-test (insets, F, H, J, K), mixed 
model with Bonferroni correction (C) or one-tailed unpaired Student’s t-test (M, 
N).  
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throughout most of the feeding timeline, there was a modest reduction in weight 
in Tg/Tg mice following 12-weeks of HFD (Fig 3.3c). Even so, there was a trend 
toward insulin sensitivity prior to changes in weight (Cooper Lab, unpublished 
data), implying intrinsic effects independent of weight loss. To further evaluate 
this discrepancy in weight, we performed metabolic cage analysis of WT and 
Tg/Tg mice fed a HFD. Though there was no difference in daily activity or food 
intake (Fig. 3.3d and 3.3e), mice with augmented hepatic OXPHOS tended to 
have increased diurnal energy expenditure (Fig. 3.3f). We, therefore, screened 
several factors involved in whole body energy balance – hepatic Fgf21, hepatic 
Il6, and skeletal muscle Irisin; however, none of the mRNAs for these factors 
could explain the changes observed (discussed in Chapter IV).  
  Since transgenic Lrpprc expression in our model is restricted to the liver (Fig. 
3.1c), we evaluated potential mechanisms by which augmented OXPHOS 
confers insulin sensitivity. Specifically we focused on ER stress, reactive oxygen 
species (ROS), and protein kinase C epsilon (PKCε) activation. As shown in 
Figure 3.3g, we saw no change in several mRNA known to correlate with ER 
stress. Regarding ROS, Ucp2 and iNOS, which are markers of oxidative stress, 
were reduced in high-fat fed Tg/Tg livers (Fig. 3.3h). Consistent with these 
results, ectopic Lrpprc expression in human hepatoma cells (HepG2 cell line) 
reduced mitochondrial superoxide  production as assessed by MitoSox Red (Fig. 
3.3i). This indicates LRPPRC is sufficient to reduce ROS formation in a cell 
autonomous fashion. Mitochondrial production of ROS is, in part, dependent on 
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inner membrane proton gradient (Korshunov et al., 1997). Cells ectopically 
expressing LRPPRC had lower proton gradients compared with controls (Fig. 
3.3j), suggesting a likely mechanism for reduced mitochondrial superoxide. 
Because coupled respiration is increased (Fig. 3.2), a reduced proton gradient 
could suggest enhanced proton pumping coupled with a disproportionately 
greater activity at complex V, which dissipates the proton gradient. This is 
consistent with previous work indicating differential effects of LRPPRC on 
Complex V (Liu et al., 2011; Mourier et al., 2014). 
  To exclude weight reduction as a potential confounding factor in insulin 
resistance, we next evaluated insulin induced phosphorylation of AKT (pAKT) in 
primary hepatocytes isolated from mice on a chow fed diet. As shown in Figure 
3.3k, primary hepatocytes from mice with augmented hepatic OXPHOS had 
modestly increased pAkt in response to insulin treatment. These data suggest 
two key findings. One, augmented hepatic OXPHOS modestly improves 
hepatocyte insulin signaling in a cell autonomous manner and lowers the 
mitochondrial proton gradient culminating in lower ROS. Two, improved 
hepatocyte signaling promotes whole body insulin signaling only in the setting of 
metabolic stress. 
  In fatty liver disease, increased triglyceride content promotes the accumulation 
of diacylglycerol (DAG) species, which in turn activates PKCε. Upon activation, 
PKCε translocates from the cytosol to the membrane, where it phosphorylates 
insulin receptor beta, culminating in impaired insulin signaling (Jornayvaz and 
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Shulman, 2012; Samuel et al., 2007). Assessment of membrane bound PKCε is, 
thus, a readout of PKCε activation and correlates with insulin resistance 
(Jornayvaz et al., 2011). Activation of PKCε was reduced in mice with augmented 
hepatic OXPHOS (Fig. 3.3l – 3.3n). These data could imply decreased total lipid 
burden in liver with augmented OXPHOS.  
 
Augmented hepatic OXPHOS protects against NAFLD 
  We hypothesized that enhanced OXPHOS might influence the course of 
NAFLD. We tested this hypothesis by feeding mice a HFD for 12 weeks to induce 
fatty liver disease. In mice, diet-induced NAFLD results in modest inflammation, 
without inducing significant fibrotic changes and full-blown NASH (Ito et al., 
2007). Nonetheless, this modest inflammation was reduced in transgenic mice 
compared with littermate control mice (Fig. 3.4a and 3.4b, p=0.16, chi-squared). 
In Tg/Tg mice, the frequency of mice with healthy livers was increased (30% 
Tg/Tg vs. 0% control). Similarly, the frequency of mice with moderate hepatic 
inflammation was reduced 2.2-fold (20% Tg/Tg mice vs. 44% control). In support 
of histological grading, the expression of panel of inflammatory genes was 
reduced in mouse liver from Tg/Tg mice (Fig. 3.4c). Notably, Ccl2 (also called 
Mcp1), a monocyte chemoattractant, was modestly reduced. 
  Next, we evaluated hepatic steatosis, using histological and biochemical 
assessments. Compared with WT littermate controls, Tg/0 and Tg/Tg mice show 
a dramatic reduction in hepatic lipid content (Fig. 3.4a and Fig 3.S4). We also   
75 
 
 
 
 
Figure 3.4 Augmented hepatic OXPHOS interdicts NAFLD. (A) 
Representative histological sections of livers from wild-type littermate control 
mice (WT) and LRPPRC double hemizygous (Tg/Tg) mice. (B) Pathologic 
classification of inflammation in livers of the same mice. (C) Expression of 
inflammatory genes in livers of WT and Tg/Tg mice fed a high-fat diet for 12 
weeks. (D) Pathologic classification of steatosis in high-fat fed WT and Tg/Tg 
mouse livers. (E) Biochemical determination of triglyceride content in the same 
samples. (F) Determination of Fsp27 expression in high-fat fed WT and Tg/Tg 
livers. (G) Serum triglyceride content in the same mice. Expression of genes 
involved in (H) lipid export, (I) lipid uptake, (J) Lipogenesis, and (K) fatty acid β-
oxidation in high-fat fed WT and Tg/Tg mouse livers. For all experiments, n = 9 or 
10. Data are mean ± SEM *p<0.05, **p<0.01, ***p<0.001 vs. WT by chi-squared 
analysis (B, D), 2-way ANOVA with Bonferroni’s post-test (C), or by two-tailed, 
unpaired Student’s t-test (D-K). 
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graded hepatosteatosis, using a well characterized grading system (Kleiner et al., 
2005).  The frequency of mice with healthy livers was markedly increased in mice 
with augmented hepatic OXPHOS (30% Tg/Tg vs 0% control) , and there was  
2.6-fold reduction in steatotic livers (30% Tg/Tg vs. 78% control, Fig. 3.4d). 
Consistent with these results, biochemical measurement of hepatic triglycerides 
and the expression of Fsp27, a gene that marks lipid size, were both reduced in 
livers from Tg/Tg mice (Fig. 3.4e and 3.4f). This reduced lipid burden may 
explain diminished PKCε activation. Taken together, these data argue that 
augmentation of hepatic OXPHOS by ectopic expression of LRPPRC mitigates 
both steatosis and inflammation in NAFLD. 
  Regulation of hepatic lipid content is complex process that is dependent on 
integrated action of lipid transport, lipogenesis, and fatty acid oxidation. For 
example, an increase in hepatic lipid export can reduce hepatic steatosis but 
adversely increase serum triglycerides (Bellafante et al., 2013; Lelliott et al., 
2007). Similarly, a decrease in hepatic lipid uptake can reduce steatosis but 
adversely increase serum triglyceride. In mice with augmented hepatic OXPHOS, 
fasting serum triglycerides were not altered (Fig. 3.4g), a finding which could 
imply that hepatic lipid export and import were not significantly altered. 
Consistent with this, genes involved in lipid transport were unchanged in Tg/Tg 
mice (Fig. 3.4h and 3.4i). 
  Because hepatic lipogenesis is increased in patients with NAFLD (Donnelly et 
al., 2005), we quantified the expression of lipogenic genes. While Srebp1c was 
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unchanged, Fasn mRNA was modestly reduced about 35% in Tg/Tg mice (Fig. 
3.4j). Even so, the difference in Fasn is unlikely to explain reduced hepatic 
steatosis in LRPPRC transgenic mice, since ablation of Fasn in mice 
paradoxically increases hepatic lipid content (Chakravarthy et al., 2005). 
Additionally, we assessed the expression of ChREBP isoforms, a transcription 
factor which regulates Fasn and Acc. However, in Tg/Tg mice, total ChREBP, 
ChREBP-a, and ChREBP-β exhibited only minor changes compared to wild-type 
littermate controls. 
  We previously showed that ectopic Lrpprc expression promotes fatty acid β-
oxidation in primary hepatocytes (Liu et al., 2011). In this model, LRPPRC 
enhanced fatty acid oxidation without affecting the expression of genes involved 
in fatty acid β-oxidation. Consistent with our previous study, the expression of 
genes involved in fatty acid β-oxidation gene were unchanged in livers Tg/Tg 
mice (Fig. 3.4k). These data imply metabolic control of fatty acid β-oxidation is 
critical. 
 
Augmented OXPHOS increases hepatic NAD+, which governs complete fatty 
acid oxidation. 
  Status of hepatic OXPHOS directly correlates with fatty acid oxidation in liver. 
For example, in patients suffering from Leigh syndrome, which impairs OXPHOS, 
there is increased hepatic steatosis and reduced β-oxidative capacity (Merante et 
al., 1993; Morin et al., 1993). Furthermore, pharmacological inhibition of 
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OXPHOS impairs mitochondrial oxidation of fatty acids (Eaton et al., 1996a). We 
previously published that ectopically expressing Lrpprc in hepatocytes increased 
OXPHOS as well as palmitate oxidation without alterations in the fatty acid 
oxidative program (Liu et al., 2011). The absence of substantial genetic changes 
in these models of OXPHOS as well as in Tg/Tg mice (Fig 3.4k) could suggest a 
metabolic control of fatty acid oxidation. We, therefore, sought to investigate if 
metabolic control via augmented OXPHOS could promote complete fatty acid 
oxidation.  
  Complete oxidation of lipids requires oxidation of acetyl-CoA by the citric acid 
cycle, a process dependent on the oxidized electron carrier NAD+ (Fig. 3.5a). 
Conversely, NADH opposes citric acid (TCA) cycle oxidation. The electron 
transport chain plays a central role in coenzyme concentration as it converts 
NADH to NAD+. Thus, we hypothesized that augmented OXPHOS might 
increase NAD+, which in turn might promote complete oxidation via the citric acid 
cycle. We measured NAD+ levels in mice with augmented OXPHOS fed a chow 
diet. As shown in Figures 3.5b and 3.5c, both Tg/0 and Tg/Tg mice had 
increased levels of NAD+ and the ratio of oxidized to reduced carriers 
([NAD+]/[NADH]). We did not, however, observe any alteration in the rate limiting 
enzymes involved in NAD+ synthesis (Fig. 3.5d).  
  Next, we confirmed these findings in a cellular model of hepatic OXPHOS. To 
exclude pleiotropic effects of LRPPRC expression, we measured the effects of 
chemical activators and inhibitors of cellular respiration on the ratio of   
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Figure 3.5 OXPHOS dictates NAD+, promoting complete oxidation of fatty 
acids (A) Fatty acid metabolic pathway in liver: NAD+ dependent β-
oxidation catalyzes lipids to acetyl-CoA and ketone bodies (incomplete 
oxidation). Acetyl-CoA is further metabolized via the NAD+ dependent TCA 
cycle, yielding CO2(complete oxidation). NAD+ allosterically activates TCA 
cycling, while NADH inhibits this process. (B) NAD+ and (C) [NAD+]/[NADH] 
levels in chow fed wild-type littermate control mice (WT), LRPPRC single 
hemizygous (Tg/0), and double hemizygous (Tg/Tg) mice.(D) NAD+ synthetic 
gene expression in WT and Tg/Tg mice. (E) [NAD+]/[NADH] levels in cultured 
primary hepatocytes treated with 250 μM palmitic acid, 1 μM rotenone, or 4 μM 
FCCP. (F) NAD+ levels in nicotinamide (NAM) treated cultured primary 
hepatocytes. (G) Palmitate oxidation to CO2 in cultured primary hepatocytes 
treated with NAM. (H) Immunoblot of citrate synthase (CS) expression in cultured 
primary hepatocytes treated with NAM. (I) Palmitate oxidation in Sirt3 -/- (Sirt3 
KO) primary hepatocytes treated with NAM. Palmitate oxidation in primary 
hepatocytes treated with (J) rotenone or (K) FCCP and NAM. For all 
experiments, n = 3 or 4 Data are mean ± SEM *p<0.05, **p<0.01, ***p<0.001 vs. 
vehicle unless otherwise indicated and ###p<0.001 by two-tailed unpaired 
Student’s t-test (B, C, E, G, I, J, K) or linear regression (F). 
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[NAD+]/[NADH] in cultured primary mouse hepatocytes. To first test the effects of 
metabolic excess on [NAD+]/[NADH], we treated hepatocytes with palmitic acid. 
Consistent with previous work in hepatoma cell lines (Noguchi et al., 2009), 
palmitate enhanced [NAD+]/[NADH] in primary hepatocytes containing normal 
respiratory capacity (Fig. 3.5e). We then wished to understand if modulation of 
cellular respiration altered [NAD+]/[NADH]. Inhibition of electron transport using 
the Complex I inhibitor rotenone significantly diminished [NAD+]/[NADH]. In 
contrast, increasing cellular respiration by the uncoupling agent FCCP enhanced 
[NAD+]/[NADH] levels. Since OXPHOS is disrupted in patients with NAFLD, we 
interrogated the consequences of nutrient excess in the context of a 
dysfunctional respiratory chain by measuring the availability of NAD+ in 
hepatocytes concurrently treated with palmitic acid and rotenone. As shown in 
Figure 3.5e, the addition of fatty acids synergistically diminished [NAD+]/[NADH] 
in hepatocytes treated with rotenone. This suggests that [NAD+]/[NADH] levels 
may only be disrupted by nutrient flux in the presence of impaired OXPHOS. 
  Given the availability of NAD+ is dictated by OXPHOS, and augmented 
OXPHOS drives fatty acid oxidation, we evaluated whether increased NAD+ 
could was the basis for complete oxidation of fatty acids. To test this, we treated 
primary mouse hepatocytes with the NAD+ precursor nicotinamide (NAM). 
Treatment with NAM directly correlated with cellular NAD+ levels in cultured 
primary hepatocytes (Fig. 3.5f). We next investigated if increased NAD+ 
promoted complete oxidation of fatty acids by measuring the complete oxidation 
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of palmitate to CO2 in the presence of increasing NAM , which increases NAD+ 
levels. As shown in Figure 3.5g, NAM promoted a dose-dependent increase in 
complete palmitate oxidation to CO2, suggesting that NAD+ is capable of driving 
fatty acid oxidation. Importantly, we did not observe any effects of NAM on 
mitochondrial content as measured by the mitochondrial protein citrate synthase 
(Fig. 3.5h).  
  Previous work indicates that NAD + activates the mitochondrial protein SIRT3, 
which deacetylates certain proteins involved in fatty acid β-oxidation and 
augments fatty acid oxidation (Hirschey et al., 2010). We, therefore, assessed if 
the effects of NAM on palmitate oxidation were entirely dependent on SIRT3. 
Consistent with previously published data, primary hepatocytes lacking Sirt3 
(Sirt3 KO) had reduced fatty acid oxidative capacity when compared with wild-
type hepatocytes (Fig 3.3i). Using NAM to increase NAD+, however, the deficit in 
Sirt3 KO hepatocytes was rescued. These data imply the effects of NAD+ on 
increasing complete fatty acid oxidation are independent of SIRT3 mediated 
deacetylation. 
  We next sought to query the effects of exogenous NAD+ in hepatocytes with 
inhibited OXPHOS. To do so, we treated primary hepatocytes with rotenone, and 
measured complete oxidation of palmitate to carbon dioxide. Rotenone reduced 
palmitate oxidation by 20% compared with vehicle treated hepatocytes (Fig. 
3.5j). In the presence of NAM, however, complete fatty acid oxidation was 
rescued in OXPHOS deficient hepatocytes. Finally, we evaluated if NAD+ was 
82 
capable of enhancing palmitate oxidation in the setting of augmented cellular 
respiration. We treated primary hepatocytes with the chemical uncoupler FCCP, 
which induces maximal respiration via uncoupling electron transport from ATP 
synthesis. FCCP driven maximal respiration promoted palmitate oxidation and 
increased CO2 production two-fold (Fig. 3.5k). This increase was potentiated in 
cells treated with NAM, indicating that NAD+ augmented complete oxidation, 
even in the setting of increased cellular respiration. Taken together, these data 
are consistent with a model of OXPHOS driven NAD+, which promotes complete 
oxidation of lipids, which may explain reduced lipid accumulation in hepatocytes 
(Fig. 3.6). 
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Figure 3.6 Activation of hepatic OXPHOS increases cellular NAD+ and 
complete fatty acid oxidation, mitigating NAFLD. In obesity and nutrient 
excess, increased ratio of reduced NADH to oxidized NAD+ inhibits complete 
oxidation of fatty acids in the liver, leading to lipid accumulation, PKCε activation, 
and insulin resistance. Augmented hepatic OXPHOS, through enhanced redox 
cycling and/or increased ATP dependent NAD+ synthesis, increases the ratio of 
[NAD+]/[NADH], thereby driving complete oxidation of fatty acids, reducing 
steatosis, and promoting insulin sensitivity. Additionally, enhanced OXPHOS 
reduces reactive oxygen species, which may contribute to increased insulin 
sensitivity (not shown). 
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Figure 3.S1 Hemizygous expression of LRPPRC promotes mitochondrial 
transcription. (A) Lrpprc, mitochondrial polymerase (Polrmt), mitochondrial 
transcription factor A (Tfam), and mitochondrial transcription factor B2 (Tfb2m) 
and (B) mitochondrially encoded respiratory complex subunit gene expression in 
hemizygous liver specific LRPPRC transgenic (Tg/0) and control livers. Data are 
mean ± SEM. *p<0.05 by Student’s unpaired two-tailed t-test (A) or 2-way 
ANOVA (B), n=4. 
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Figure 3.S2 LRPPRC increases respiratory complex activity. Individual 
electron transport chain complex activity of NADH-ubiquinone oxidoreductase 
(CI), ubiquinol-cytochrome c reductase (CIII), cytochrome c oxidase (CIV), and 
ATPase (CV) in control (LacZ) vs. LRPPRC replete samples, normalized to 
citrate synthase activity (CS). Citrate synthase activity was unchanged between 
groups. Data are mean ± SEM. p<0.05 by two-way ANOVA, n=3. 
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Figure 3.S3 Effects of LRPPRC on OXPHOS are maintained after high-fat 
feeding. (A) Relative Lrpprc and (B) mitochondrially encoded respiratory subunit 
gene expression in livers of wild-type (WT) and double-hemizygous liver-specific 
Lrpprc transgenic mice fed a high-fat diet. (C) Protein expression in the same 
samples. Data are mean ± SEM. *p<0.05 by Student’s unpaired two-tailed t-test 
(A) or 2-way ANOVA (B), n=3-4. 
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Figure 3.S4 Hemizygous expression of LRPPRC demonstrates moderate 
protection from NAFLD. (A) Representative H+E and (B) pathologic grading of 
wild-type (WT) and hemizygous liver-specific LRPPRC transgenic mice (Tg/0) 
fed a high-fat diet for 12 weeks, n = 8–10 for WT and n = 6 for Tg/0. Data are 
mean ± SEM. *p<0.05 by chi-square analysis.  
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Discussion 
 
  In this report, we demonstrated that increased hepatic oxidative phosphorylation 
(OXPHOS) increases NAD+, an allosteric activator of TCA cycle enzymes, which 
promotes complete oxidation of fatty acids. Consistent with a favorable change in 
hepatic lipid homeostasis through NAD+, mice with augmented hepatic OXPHOS 
had increased NAD+ and were protected from NAFLD. Increasing NAD+ in 
mouse hepatocytes rescued incomplete fatty acid oxidation in mice deficient for 
either OXPHOS or SIRT3 and synergistically increased complete oxidation of 
fatty acids in hepatocytes with increased cellular respiration. As reported by 
others, mitigation of NAFLD was associated with improved whole-body insulin 
sensitivity, presumably due to reduced liver inflammation and release of 
detrimental inflammatory cytokines. Overall, these data identify a critical role for 
OXPHOS-mediated control of NAD+ in NAFLD (Fig. 3.6). 
  Several studies have demonstrated that the ratio of [NADH]/[NAD+] is increased 
in NAFLD (Kendrick et al., 2011; Kim et al., 2011). Interestingly, in our studies, 
simply fluxing hepatocytes with palmitate did not did not increase the 
[NADH]/[NAD+] ratio. In the presence of impaired OXPHOS, however, the ratio 
was synergistically increased. This is important, since the ratio of [NADH]/[NAD+] 
directly correlates with mitochondrial reactive oxygen species (ROS), an 
important determinant of hepatic insulin resistance. These data may imply that 
nutrient excess coupled with OXPHOS defects determine the severity of NAFLD. 
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  The mechanism by which enhanced OXPHOS increases the [NAD+]/[NADH] is 
yet unclear. It is plausible that enhanced cycling of NADH through complex I of 
the electron transport chain yields an increase in oxidized carrier intermediates. 
Loss of complex I in some studies (Karamanlidis et al., 2013), as well as our data 
from rotenone inhibition, substantiate that complex I function is critical for 
maintaining [NAD+]/[NADH]. Interestingly, mice with enhanced hepatic OXPHOS 
also have increased total NAD+ pools, possibly suggesting an alteration in NAD+ 
metabolism. Illustrating the complexity of this regulation, Karamanlidis et al., 
recently reported that complex I deficiency reduced the [NAD+]/[NADH] ratio but 
also perturbed the pool size. These observations suggest that the regulation of 
NAD+ and NADH is complex, presumably because it is governed by many 
variables. In our study, we did not observe any alteration in the rate limiting NAD+ 
synthetic genes. Ectopic expression of LRPPRC increases intracellular ATP, a 
co-factor critical for NAD+ synthesis. It is, thus, conceivable that enhanced 
OXPHOS increases cellular ATP, which in may in turn promote NAD+ synthesis. 
Coupled with enhanced cycling at complex I, this could explain the increase in 
both total pool size and [NAD+]/[NADH] ratio.  
  In our model which is protected against NAFLD and insulin resistance, 
respiration is coupled, indicative bona fide OXPHOS. Shulman and colleagues, 
however, showed that uncoupling cellular respiration in mice was associated with 
improved insulin sensitivity (Perry et al., 2013; Samuel et al., 2004). Our work 
illustrates that augmenting cellular respiration, whether coupled (that is, bona fide 
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OXPHOS) or uncoupled, increases the ratio of [NAD+]/[NADH], implying a 
common mechanism whereby respiration-mediated control of NAD+, which 
governs complete oxidation of fatty acids and interdicts hepatic steatosis. This is 
important, because prior studies indicate that treatment with NAD+ precursors 
niacin or nicotinamide mononucleotide may have beneficial effects on fatty liver 
(Canto et al., 2012; Ganji et al., 2014). These effects are thought to be, in part, 
dependent on activation of the sirtuin family of deacetylases. Here we have 
demonstrated that cellular NAD+ is capable of promoting fatty acid oxidation in 
the absence of the mitochondrial sirtuin SIRT3. Moreover, we did not observe 
any effects on mitochondrial biogenesis, a downstream effect of nuclear sirtuin 
SIRT1 activation. NAD+, is a potent activator of TCA cycle enzymes, whereas 
NADH is an inhibitor. It is conceivable that increasing the ratio of [NAD+]/[NADH] 
or possibly increasing the absolute concentration of NAD+, might stimulate TCA 
enzymes and promote complete oxidation of fatty acids, independent of the 
activation of sirtuin proteins. Supporting a central role for NAD+ levels, increasing 
NAD+ in OXPHOS deficient hepatocytes rescued complete fatty acid oxidation in 
Sirt3 knockout primary hepatocytes. Despite these observations, we cannot 
exclude other potentially salutary effects of increasing NAD+ that could enhance 
fatty acid oxidation in hepatocytes. 
  Other studies have manipulated mitochondrial content in the context of NAFLD, 
however, these manipulations have pleiotropic effects that confound 
interpretation. For example, ectopic expression of the transcriptional co-activator 
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PGC-1β in mouse liver improved hepatic steatosis (Bellafante et al., 2013; Lelliott 
et al., 2007), but also induced enzymes involved in lipid export. Hence, it is 
unclear how significant OXPHOS per se was in this experimental model.  More 
importantly, increased hepatic lipid secretion in this model might adversely affect 
cardiovascular health, an adverse change in serum lipids we did not observe in 
our mouse model which specifically augments OXPHOS. Other studies have 
evaluated the role of OXPHOS in fatty liver by ablating OXPHOS in mouse liver 
(Pospisilik et al., 2007). Ablation of OXPHOS in liver, however, is almost 
universally associated with reduced fat mass. Adiposity is a potent regulator of 
whole-body insulin sensitivity. It is, thus, possible that marked reductions in fat 
mass in models of impaired hepatic OXPHOS may offset adverse changes in 
liver. In our model of augmented OXPHOS, we saw a modest decline in weight. 
Even so, we suspect weight changes were not a major factor in our findings, as 
single and double transgenic mice had nearly identical weights, however, 
mitigation of NAFLD and insulin resistance was greatest only in double 
transgenic mice. Moreover, changes trending toward insulin sensitivity preceded 
changes in weight. 
  In summary, activation of hepatic OXPHOS increases NAD+ and interdicts 
NAFLD. The ratio of [NAD+]/[NADH] is dictated by cellular respiration and 
increases in NAD+ promote complete oxidation of fatty acids. These changes are 
ultimately associated with reduced cellular ROS, less activation of PKCε, and 
reduced inflammation, changes we believe promote whole-body and hepatic 
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insulin sensitivity. OXPHOS-mediated control of NAD+ may prove a safe and 
effective means to interdict NAFLD.   
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CHAPTER IV: HEPATIC OXPHOS TRANSCRIPTIONALLY REGULATES BILE 
ACIDS AND PROTECTS AGAINST DIET INDUCED OBESITY 
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Introduction 
 
  Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent medical 
issue in Western countries. Estimates indicate NAFLD has over-taken other 
causes of liver disease in total cost-burden to the medical system (Whalley et al., 
2007). NAFLD encompasses a spectrum of disease from simple hepatic lipid 
deposition, or steatosis, to inflammation and fibrosis. Patients with NAFLD are 
predisposed to liver failure and cirrhosis, which, while rare, are accompanied by 
serious complications. As numbers of people with NAFLD continue to mount, so 
will the burden of associated medical complications, making NAFLD 
pathophysiology an important subject of study. Nevertheless, to date, the precise 
mechanisms behind the development and progression of NAFLD remain unclear.   
 
  Recent studies have expanded the role for the liver to regulation of whole body 
metabolism. Hepatic insulin resistance precedes peripheral insulin resistance 
(Kraegen et al., 1991), and can interfere with whole-body glucose homeostasis 
(Michael et al., 2000). Moreover, the discovery of pro-thermogenic signaling by 
molecules such as Fgf21 (Kharitonenkov et al., 2005) and bile acids (Watanabe 
et al., 2006), provide evidence for hepatic control of whole body energy 
expenditure. Of note, bile acid production is perturbed in patients with fatty liver 
disease (Gustafsson et al., 2005; Lai et al., 2015; Patti et al., 2009). Additionally, 
a retrospective cohort study revealed brown adipose tissue activity is negatively 
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associated with NAFLD (Yilmaz et al., 2011), which could suggest a connection 
between steatosis and reduced adipocyte thermogenesis. Prevention of NAFLD, 
therefore, may have beneficial effects beyond liver health itself. 
  Bile acid synthesis is primarily governed by the expression of the rate limiting 
enzyme CYP7A1 (Chiang, 2009). Expression of Cyp7a1 is tightly regulated by a 
negative feedback loop (Goodwin et al., 2000; Makishima et al., 1999; Parks et 
al., 1999; Wang et al., 1999). Following a meal, bile acids are excreted into the 
intestinal tract, where they bind lipids. Resorption of bile acids in the ileum 
triggers a signaling feedback, which inhibits the action of transcription factors, 
such as Hepatocyte Nuclear Factor alpha (HNF4α) and the Liver X Receptor 
(LXR), on the Cyp7a1 promoter. In the fasted state, this negative regulation is 
lifted and transcription occurs. Thus, through precise modulation of Cyp7a1 
transcription, the liver governs bile acid synthesis and composition. 
   Defective hepatic oxidative phosphorylation (OXPHOS) is a distinctive feature 
of NAFLD. In particular, NAFLD is accompanied by decreased OXPHOS 
enzymatic activity (Perez-Carreras et al., 2003), diminished ATP generation 
(Cortez-Pinto et al., 1999), and altered mitochondrial structure (Caldwell et al., 
1999; Sanyal et al., 2001). We have previously examined the effects of enhanced 
hepatic OXPHOS in the setting of NAFLD using the mitochondrial transcriptional 
co-activator LRPPRC. Expression of LRPPRC promotes the formation of mature 
electron transport chain complexes resulting in increased OXPHOS activity (Akie 
et al., 2015; Liu et al., 2014; Liu et al., 2011). Using mice transgenic for liver-
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specific LRPPRC, we previously reported that enhanced hepatic OXPHOS 
mitigates NAFLD and enhances insulin sensitivity in mice (Akie et al., 2015). In 
the present study, we investigate if these alterations convey changes in whole-
body metabolism and interdict the effects long-term high-fat feeding. Our results 
demonstrate a striking protection from obesity in mice with enhanced hepatic 
OXPHOS, accompanied by alterations in bile acids and activation of oxidative 
genes in adipose tissue. OXPHOS exacts these effects via alterations in bile acid 
synthetic enzymes, which are activated by the NAD+ sensing deacetylase 
SIRT1. In contrast, mice with diminished OXPHOS had reciprocal alterations in 
bile acid composition, alterations which were similar to those of mice fed a high-
fat diet. These results suggest that the status of hepatic OXPHOS may regulate 
the bile acid synthetic program, thereby dictating whole body energy expenditure 
via adipose thermogenesis. 
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Materials and Methods 
 
Animal Model 
  Liver-specific Lrpprc transgenic mice have been described in detail elsewhere 
(Akie et al., 2015; Liu et al., 2011). Mice were housed in a 12h light/12h dark 
cycle facility. High fat feeding was initiated using male mice aged 7 weeks. Mice 
were fed a 55% kcal from fat diet (Harlan Teklad TD-93075) for the duration 
indicated. Metabolic analysis was performed by the University of Massachusetts 
Medical School Mouse Metabolic Phenotyping Center according to the facility’s 
standard protocols. At the termination of the experiment, mice were sacrificed by 
CO2 euthanasia and tissues cryopresevered in liquid nitrogen. The IACUC of the 
University of Massachusetts Medical School approved all animal experimentation 
(Protocol #A-2085-12). 
 
Bile Acid Analysis 
  Bile acid composition was performed by The Metabolomics Innovation Core 
(Alberta, Canada) as follows: The sera from each animal were pooled and vortex 
mixed.  A 50-μL aliquot of each serum sample was spiked with 50 μL of a 
predefined amount of a mix of 14 deuterium-labeled BA internal standards, 50 μL 
of water and 350 μL of acetonitrile. After vortex mixing, 1-min sonication in an ice 
water bath and centrifugation, the supernatants were collected for sample 
cleanup with phospholipid-depletion solid phase extraction in a 96-well plate 
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format using a protocol described in the publication (Han et al., 2015). The flow-
through fractions were collected and then dried under a gentle nitrogen gas flow. 
The residues were dissolved in 500 μL of 50% methanol.  20 μL were injected for 
UPLC-MRM/MS quantitation according to the procedure described in the same 
publication.   
  Each of the liver samples was homogenized in LC/MS grade water, 300 μL per 
100 mg of the raw material.  Bile acids were extracted by addition of acetonitrile 
at a ratio of 700 μL per 100 mg tissue. After extraction with vortex mixing and 1-
min sonication in an ice water bath, the samples were centrifuged at 12,500 rpm 
for 20 min in a 4 °C microcentrifuge.  100 μL of the supernatants were mixed with 
50 μL of the internal standard mix of 14 deuterium-coded bile acids and 350 μL 
of 70% acetonitrile-0.3% formic acid, the mixtures were subjected to 
phospholipid-depletion solid-phase extraction in a 96-well plate format using the 
same protocol.  The flow-through fractions were collected and then dried under a 
gentle nitrogen gas flow. The residues were dissolved in 200 μL of 50% 
methanol.  20 μL were injected for UPLC-MRM/MS.   
  A Dionex UPLC system coupled to an AB Sciex 4000 QTRAP mass 
spectrometer was operated in the electrospray ionization (ESI) - negative ion 
multiple-reaction monitoring (MRM) mode.  UPLC separation was carried out on 
a 15-cm long C-18 UPLC column with water-acetonitrile-0.01% formic acid as the 
mobile phase for binary gradient elution according to a UPLC-MRM/MS method 
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that was developed and validated (Han et al., 2015).  The column temperature 
was 45 °C and the flow rate was 0.35 mL/min.   
 
Gene and Protein Expression Analysis 
  Techniques for mRNA and protein expression analysis have been described in 
detail elsewhere (Akie et al., 2015; Liu et al., 2011). Briefly, for gene expression 
analysis, tissues were lysed in Trizol (Invitrogen) and purified using a GeneJet 
Column (Thermo Scientific). After High Capacity Reverse Transcription (Applied 
Biosystems) cDNA synthesis, RT-qPCR was performed on a Applied Biosystems 
7500 Fast instrument. Protein extracts were homogenized in lysis buffer using a 
Tissue Lyser (Qiagen), then separated by SDS-PAGE and transferred to PVDF 
membranes. Relative protein levels were detected by immunoblot as previously 
described (Liu et al., 2011). Antibodies for HNF4α (H-171), LXR (H-144) (Santa 
Cruz), phospho-p38, p38, SIRT1 (Cell Signaling) and Actin (Sigma Aldrich) were 
used according to the manufacturers specifications. 
 
Serum T3 Levels 
  Levels of triiodothyronine were measured in mouse serum by ELISA 
(Calbiotech) according to the manufacturer’s specifications. 
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Chromatin Immunoprecipitation 
 Mouse livers were rinsed briefly in cold PBS, minced, and fixed in 57.1 μL of 
fresh 18.5% paraformaldehyde by rocking for 10 minutes at room temperature. 
Fixation was quenched by addition of 117.5 μL of 1.25M glycine, and rocked for 
an additional 5 minutes. Livers were then placed on ice and homogenized using 
a motor-driven Teflon homogenizer at 30% output (5x forward, 5x reverse). 
Samples were transferred to a fresh tube and centrifuged for 5 minutes at 
1200rpm, 4 °C. The supernatant was removed and the pellet washed 2x with 
cold PBS. After the final wash, pellets were resuspended in 1 mL of RSB (3mM 
MgCl2 10mM NaCl, 10mM Tris pH 7.4, 0.1% NP-40) containing fresh protease 
inhibitor and homogenized at 40% output (15x forward, 15x reverse). Nuclei were 
swelled on ice for 5 minutes, the centrifuged at 600 rcf, 5 minutes, 4 °C. The 
supernatant was discarded and the nuclei resuspended in 200 μL Nuclear Lysis 
Buffer (1% SDS, 10mM EDTA, 50mM Tris pH 8.1). Nuclei were swollen on ice for 
20 minutes, then sonicated in a BioRuptor (Diagenode) on high power 30 sec 
on/30 sec off for 20 minutes at 4 °C. Next, 50 μL of sonicated chromatin was pre-
cleared with 6 μg of Normal Rabbit IgG + 2 μg sonicated salmon sperm DNA + 
50 μL of 1:1 Protein A/G slurry in 1 mL of ChIP Dilution Buffer (1% Triton X-100, 
2mM EDTA, 150mM NaCl, 20mM Tris pH 8.0) for 2 hours at 4 °C. Following pre-
clearing, beads were pelleted by centrifugation at 1000 rpm x 3 minutes, 4 °C. 
The supernatant was transferred to a fresh tube; 20 μL was reserved as “input” 
and stored at -80 °C. The remaining sample was incubated overnight with 2 μg of 
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antibody, rocking at 4 °C. The next morning, 50 μL of Protein A/G slurry + 2 μg 
sonicated salmon sperm was added to the samples and allowed to rock at 4 °C 
for 1.5 hours. Samples were centrifuged 3 minutes at 1000 rpm, 4 °C. Beads 
were sequentially washed for 20 minutes at room temperature with 1 mL of each 
of the following: Low Salt ChIP Buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 
20mM Tris pH 8.1, 150 mM NaCl), High Salt ChIP Buffer (0.1% SDS, 1% Triton 
X-100, 2mM EDTA, 20mM Tris pH 8.1, 500 mM NaCl), LiCl ChIP Buffer (0.25M 
LiCl, 1% NP-40, 1% Sodium deoxycholate, 1mM EDTA, 10mM Tris pH 8.1), then 
washed three times for 5 minutes in TE pH 8.0. Chromatin was eluted from the 
beads three times in 100 μL of fresh 1% SDS + 0.1M NaHCO3 and pooled in a 
microcentrifuge tube. 12 μL of 5M NaCl was added to the pooled eluate, and 80 
μL of water plus 4 μL of 5M NaCl was added to the thawed inputs. Samples were 
decrosslinked at 65 °C overnight. DNA was purified by PCR Purification Column 
(Qiagen) and eluted twice with 50 μL of water. Samples were analyzed by qPCR 
as described previously. 
 
Adenoviral Transduction 
  Adenoviral injection was performed as previously described (Liu et al., 2014) 
with 8 x 109 pfu / mouse. Animals were allowed to recover 5 days, then livers 
were harvested and gene expression analyzed as above. Adeno-associated virus 
(AAV) injection was performed as previously described (Liu et al., 2014) with 1 x 
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1011 GC / mouse. Tissues from injected animals were harvested 3 weeks 
following injection. 
 
Reporter Assay 
  Reporter assays were performed in HepG2 human hepatoma cells. The 
hCYP7A1-Luciferase reporter construct was the kind gift of J.Y. Chiang (Wang et 
al., 1996). Transient transfections were performed using Lipofectamine (Life 
Technologies) as previously described (Cooper et al., 2006). Relative luciferase 
activity was analyzed by Luciferase Assay System (Promega) according to the 
manufacturers protocol and normalized to a co-transfected RSV β-galactosidase 
internal control. Where appropriate, cells were incubated in the presence of 10 
μM EX-527 for 16 hours immediately prior to analysis. 
 
Statistics 
  Analyses were carried out in Prism (GraphPad). Differences between groups for 
all data sets were determined by either Student’s t-test or two-way ANOVA with 
Bonferonni post-hoc analysis, as indicated in the figure legends. For all assays, a 
p<0.05 was deemed to be significant. 
 
  
104 
Results 
 
Enhanced Hepatic OXPHOS Protects Against Diet-Induced Obesity 
  Our lab has previously established a mouse model of enhanced hepatic 
OXPHOS (Tg/Tg mice) using liver-specific overexpression of the mitochondrial 
transcriptional co-activator LRPPRC (Akie et al., 2015; Liu et al., 2011). These 
mice were protected from high fat diet induced hepatic steatosis, inflammation, 
and glucose intolerance. Interestingly, we observed an increase in diurnal energy 
expenditure in these mice without alterations in activity, indicative of an increase 
in basal metabolic rate. Thus, to test the effects of enhanced hepatic OXPHOS 
over long-term exposure to high fat diet, we extended our feeding timeline. 
Consistent with an increase in diurnal energy expenditure, Tg/Tg mice weighed 
significantly less than their wild-type littermates after long-term high fat feeding 
(Fig. 4.1A). Magnetic resonance spectroscopy analysis revealed that mice with 
enhanced hepatic OXPHOS tended to be leaner, with reduced fat mass and 
increased lean-body mass (Fig. 4.1B and 4.1C). These mice also had 
significantly less visceral fat, as measured in the epididymal fat pad (Fig. 4.1D). 
Thus, consistent with our previous findings of increased energy expenditure, 
mice with enhanced hepatic OXPHOS are protected from the obesogenic effects 
of long-term high fat feeding. 
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Figure 4.1 Hepatic OXPHOS protects against diet induced obesity. (A) Body 
weight of wild-type (WT) and LRPPRC transgenic mice (Tg/Tg) fed a high fat diet 
for the time indicated. (B) Body fat, (C) lean mass, and (D) epididymal fat pad 
size, expressed as percent body weight, in WT and Tg/Tg mice fed a high fat diet 
for >20 weeks. (E) Serum triiodothyronine levels in the same mice. (F) 
Expression of brown adipose tissue Bmp7, (G) skeletal muscle Irisin, and (H) 
liver Fgf21 in high-fat fed WT and Tg/Tg mice. *p<0.05 by Student’s t-test, n=3-5.  
  
106 
Hepatic OXPHOS Determines Bile Acid Composition 
  Numerous endocrine factors can promote whole-body energy expenditure. To 
better understand how hepatic OXPHOS might be exert these effects, we probed 
several known mediators of increased energy expenditure. The thyroid hormone 
triiodothyronine plays an important role in regulating whole body energy 
homeostasis (McAninch and Bianco, 2014). Since the liver synthesizes several 
thyroid transport proteins, we first investigated if serum T3 was altered. As shown 
in Figure 4.1E, serum T3 levels did not differ between Tg/Tg mice and controls. 
  Recent studies have identified several novel regulators of adipose 
thermogenesis. In adipose tissue, increased levels of Bmp7 promote 
differentiation and energy expenditure (Tseng et al., 2008). Additionally, the 
muscle derived factor Irisin, when secreted, promotes browning of white adipose 
tissue resulting in thermogenesis (Bostrom et al., 2012). We, thus, examined the 
levels of each of these factors, however, compared to controls, they were 
unchanged in Tg/Tg mice (Fig. 4.1F and 4.1G). The production of Fgf21 within 
the liver protects from high-fat feeding and hepatic steatosis via both brown-fat 
mediated energy expenditure and effects independent of brown adipose tissue 
(Inagaki et al., 2005; Kharitonenkov et al., 2005; Samms et al., 2015; Veniant et 
al., 2015). We therefore probed whether Fgf21 was altered in our model. 
Interestingly, mice with enhanced hepatic OXPHOS had a significant reduction in 
Fgf21 expression (Fig. 4.1H). This decrease in Fgf21 may reflect a reduction in 
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hepatic lipid burden, as fatty liver correlates with serum FGF21 levels in both 
mice and humans (Li et al., 2011c).   
  Understanding of bile acid biology has expanded from a primary role in dietary 
lipid absorption to a network of metabolic pathways thanks to the discovery of 
bile acid-specific receptors (Kawamata et al., 2003; Parks et al., 1999). Of 
particular interest, the bile acid receptor TGR5 activates brown adipose tissue 
through local production of T3 (Watanabe et al., 2006). Since bile acids are 
synthesized almost exclusively in the liver, we reasoned that alteration of bile 
acid composition might connect hepatic OXPHOS to increased energy 
expenditure. To test this hypothesis, we profiled bile acid composition in high fat 
diet fed WT and Tg/Tg mice. As shown in Figure 4.2A, both serum and liver bile 
acid composition was altered in mice with hepatic OXPHOS. Importantly, we 
found an increased proportion of chenodeoxycholic acid in Tg/Tg livers, a 
species known to activate TGR5 and promote energy expenditure (Broeders et 
al., 2015). 
  Since mice with liver-specific overexpression of LRPPRC were generated using 
random transgene insertion, we wanted to validate the results that hepatic 
OXPHOS regulates bile acid composition in a model of reduced OXPHOS. To do 
this, we expressed liver-specific Cre recombinase in adult Lrpprc flox/flox mice 
using an injectable adeno-associated viral vector (Liu et al., 2014). Consistent 
with a role for OXPHOS in the regulation of bile acid composition, mice deficient 
for LRPPRC had altered bile acid composition (Fig 4.S1). Moreover, when   
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Figure 4.2 Enhanced hepatic OXPHOS alters bile acid composition and 
promotes oxidative gene expression in adipose tissue. (A) Relative bile acid 
composition in liver and (B) serum of WT and Tg/Tg mice fed a high-fat diet, n = 
4. Oxidative gene expression in (C) brown adipose tissue (BAT), (D) epididymal 
white adipose tissue (EWAT), and (E) skeletal muscle, n = 8-10. *p<0.05, 
**p<0.01 by Student’s t-test.  
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compared with changes in Tg/Tg mice, liver-specific LRPPRC knockout mice had 
reciprocal changes in several species including reductions in cholic acid, 
chenodeoxycholic acid and increased proportions of taurodeoxycholic acid. 
Taken together, these data suggest levels of hepatic OXPHOS regulate bile acid 
composition in vivo. 
 
Liver OXPHOS Promotes an Oxidative Phenotype in Adipose Tissue 
  Bile acids promote energy expenditure via TGR-5 mediated effects on adipose 
tissue (Broeders et al., 2015; Watanabe et al., 2006). This prompted us to 
investigate if increased energy expenditure in enhanced hepatic OXPHOS may 
be a result of altered adipose tissue metabolism. We, therefore, screened a 
panel of thermogenic genes in brown adipose tissue from Tg/Tg mice and 
controls. While we did not observe changes in Ucp1, we did observe a significant 
induction of Dio2, the gene which encodes the tissue iodothyronine deiodinase 
(Fig. 4.2D). This is important, since Dio2 expression is responsible for local 
conversion of thyroxine (T4) to its active form triiodothyronine (T3), a process 
required for thermogenesis (de Jesus et al., 2001; Watanabe et al., 2006). 
Additionally, brown adipose tissue from Tg/Tg mice had increased expression of 
Pgc-1a and Prdm16, expression of which promotes brown fat activation 
(Puigserver et al., 1998; Seale et al., 2007). Examination of gene expression in 
epididymal white adipose tissue also revealed significant induction of Pgc-1a as 
well as several genes involved in oxidative metabolism, consistent with increased 
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adipose thermogenesis (Fig. 4.2E). We did not observe alterations in oxidative 
genes in muscle from Tg/Tg mice (Fig. 4.2F), suggesting metabolic alterations 
driven by hepatic OXPHOS are specific to adipose tissue. These data are in line 
with other models of bile acid-induced energy expenditure, which had effects in 
adipose tissue without alterations in muscle (Li et al., 2010c). 
 
Regulation of Bile Acid Synthesis by a SIRT1 – PGC-1α – HNF4α Axis 
  The synthesis of bile acids within the liver is regulated by a host of molecules 
which modulate the expression of synthetic enzymes (Chiang, 2009). We sought 
to better understand the mechanism by which hepatic OXPHOS alters bile acid 
composition in Tg/Tg mice. Thus, we first examined the gene expression of 
several transcription factors which regulate bile acid synthesis (Fig. 4.3A). 
However, none of these differed between wild-type and Tg/Tg animals. We 
further examined the protein levels of two major regulators of bile acid synthesis, 
HNF4α and LXR, which were expressed similarly between groups (Fig. 4.3B). 
MAP kinase activation induces JNK-mediated expression of the repressor SHP, 
thereby inhibiting transcription of bile acid synthetic genes (Gupta et al., 2001). 
However, SHP gene expression was unchanged in Tg/Tg animals (Fig. 4.3A) 
suggesting this pathway is unlikely to regulate OXPHOS-mediated expression of 
Cyp7a1. Additionally, activation of p38 MAPK has been shown to alter Cyp7a1 
expression (Xu et al., 2007), but we did not observe alterations phospho-p38 in 
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Figure 4.3 Expression of bile acid regulatory transcription factors is 
unaltered by enhanced OXPHOS. (A) Hepatic gene expression of transcription 
factors know to alter bile acid synthesis liver X receptor (Lxr), farnesoid X 
receptor (Fxr), pregnane X receptor, liver receptor homolog 1 (Lrh-1), hepatocyte 
nuclear factor 4 alpha (Hnf4a), small heterodimer partner (Shp) in WT and Tg/Tg 
mice fed a high fat diet. (B) Protein expression in livers of the same mice. (C) 
Chromatin immunoprecipitation by HNF4α on the promoters of Cytochrome C 
(negative control), pyruvate carboxylase (Pcx), phosphoenolpyruvate 
carboxykinase (Pepck), cytochrome P450 7a1 (Cyp7a1), glucose-6-phosphatase 
(G6pase), glucokinase (Gck). *p<0.05 by Student’s t-test, n=3-4. 
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Tg/Tg animals (Fig. 4.3B). Finally, expression of bile acid synthetic genes could 
be the result of altered DNA docking by HNF4α on target promoters. To test this, 
we performed ChIP of HNF4α on known promoter sequences. While the 
presence of HNF4α was increased on the promoter of gluconeogenic gene 
G6pase, we did not observe differential binding for other promoter sequences 
analyzed, including Cyp7a1, the major regulatory gene in bile acid synthesis 
(Fig. 4.3C). This argues against altered DNA binding by HNF4α as a mechanism 
for altered bile acid composition. 
  The activity of HNF4α is regulated by post translational modifications and 
interaction with transcriptional co-activators.  One well known regulator of HNF4α 
activity is the transcriptional co-activator PGC1-α (Rha et al., 2009; Rhee et al., 
2006). Previous reports indicate that overexpression of PGC-1α induces Cyp7a1 
expression in cells (Shin et al., 2003). To first test in vivo the sufficiency of PGC-
1α to induce the bile acid synthetic program, we performed transduction of 
mouse livers vial tail-vein injection of either control (AdGFP) or PGC-1α (AdPGC-
1a) adenovirus. As shown Figure 4.4A, ectopic expression of PGC-1α resulted in 
a significant induction of Cyp7a1 and a trend toward increased Cyp8b1. We 
therefore examined whether expression of PGC-1α was altered in our mice, 
however, there was no such difference (Fig. 4.4B).  
  PGC-1α is regulated by several post-translational modifications which can 
influence binding to transcription factors (Liu and Lin, 2011). In liver, de-
acetylation of PGC-1α by the NAD+-dependent deacetylase SIRT1 is essential   
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Figure 4.4 A SIRT1 – PGC-1α – HNF4α axis regulates bile acid synthesis. 
(A)Gene expression in livers of mice tail-vein injected with adeno-viral vectors 
expressing GFP (AdGFP) or PGC-1α. (B)Ppargc1a (Pgc-1α) expression in livers 
of WT and Tg/Tg mice fed a high-fat diet. (C) SIRT1 target gene expression in 
the same samples. (D) SIRT1 gene expression in livers high fat fed WT and 
Tg/Tg mice. (E) Relative luciferase activity in HepG2 cells expression HNF4α or 
SIRT1 ± 10μM EX-527 and (F) in the presence or absence of PGC-1α. *p<0.05 
**p<0.01 by two-way ANOVA (A) or Student’s t-test (B-D), n=3-4.   
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for induction of the gluconeogenic response by PGC-1α during fasting (Rodgers 
et al., 2005). We therefore queried if SIRT1 was activated in livers of mice with 
enhanced hepatic OXPHOS by examining the expression of genes known to be 
regulated by SIRT1 (Fig. 4.4C). Consistent with SIRT1 activation, livers of Tg/Tg 
mice had increased expression of the fasting genes G6pase and Pepck. 
Additionally, the PGC-1α regulated bile acid synthetic genes Cyp7a1, Cyp8b1 
were induced in Tg/Tg livers (Bhalla et al., 2004; Wiwi and Waxman, 2005). We 
also observed a significant reduction in several genes known to be down-
regulated by SIRT1 activation: Cyp3a11 and Cyp2b10 (Buler et al., 2011; 
Goodwin et al., 2003).  
  Since SIRT1 protein levels are stabilized with activation (Rodgers et al., 2005), 
we further probed SIRT1 activation in Tg/Tg mice by immunoblot. In support of 
SIRT1 activation, protein levels were increased in mice with enhanced hepatic 
OXPHOS (Fig. 4.4D). We have previously demonstrated that mice enhanced 
hepatic OXPHOS increased of [NAD+] in liver (Akie et al., 2015), which is 
consistent with the activation of SIRT1 observed here. In mice deficient for 
OXPHOS,  
  In mice deficient for OXPHOS, the reciprocal changes in bile acid composition, 
led us to hypothesize that these mice should have evidence of diminished SIRT1 
activation and reduced NAD+ levels. As shown in Figure 4.S2, livers of LRPPRC 
knockout mice showed elevation of Cyp2b10 and significantly lower levels of 
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hepatic NAD+. Together these data indicate levels of OXPHOS modulate NAD+ 
levels, thereby influencing SIRT1 activity in liver.  
  To evaluate the transcriptional connection between activated SIRT1 and bile 
acids, we performed a Cyp7a1 reporter assay in liver-derived cell lines. In the 
absence of PGC-1α, addition of SIRT1 to HNF4α failed to potentiate Cyp7a1 
transcription, indicating that SIRT1 alone is insufficient to drive expression (Fig. 
4.4E). Moreover, the addition of PGC-1α alone induced only a slight increase in 
Cyp7a1 activation (Fig. 4.4F). Addition of PGC-1α in the presence of SIRT1, 
however, showed robust activation of the Cyp7a1 promoter (Fig. 4.4F). 
Moreover, this activation was completely blunted by the SIRT1 inhibitor EX-527, 
suggesting a SIRT1 specific effect. Importantly, addition of EX-527 to HNF4α or 
SIRT1 alone had no effect (Fig. 4.4E). Taken together, our data point to a 
transcriptional axis, whereby enhanced hepatic OXPHOS augments cellular 
NAD+, activating SIRT1-PGC-1α mediated bile acid synthesis, culminating in 
protection from obesity (Fig. 4.5).  
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Figure 4.5 Enhanced hepatic OXPHOS transcriptionally regulates bile acids 
promoting leanness. We have previously demonstrated that enhanced hepatic 
increases cellular NAD+ content and mitigates NAFLD. In the present study, we 
provide evidence for a transcriptional regulation of bile acids by hepatic 
OXPHOS, whereby augmentations in [NAD+] activate SIRT1 – PGC-1α – HNF4α 
mediated expression of CYP7A1, culminating in adipose tissue activation and 
leanness. (Adapted from Akie TE et al., PLoS One, 2015) 
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Figure 4.S1 Deficient hepatic OXPHOS alters bile acid composition similar 
to high fat feeding. Bile acid composition in livers of chow fed wild-type (WT) 
and LRPPRC flox/flox mice (LKO) injected with AAV-TBG-Cre, and wild-type 
mice fed a high fat diet (HFD). LKO vs. WT p<0.001, HFD vs. WT p<0.001 by 
two-way ANOVA, n=4.  
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Figure 4.S2 NAD+ and SIRT1 activation are diminished in livers with 
OXPHOS deficiency. (A) SIRT1 target gene expression and (B) NAD+ levels in 
livers of WT and LKO mice fed a chow diet. *p<0.05, **p<0.01 by Student’s t-test. 
n=4-5. 
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DISCUSSION 
 
  Here we demonstrate enhanced hepatic oxidative phosphorylation (OXPHOS) 
protects from diet induced obesity, promoting leanness in mice fed a high fat diet. 
Mice with enhanced hepatic OXPHOS had altered bile acid composition and 
enhanced adipose oxidative metabolism, protective factors under metabolic 
stress. Conversely, diminished OXPHOS in liver induced reciprocal changes in 
bile acids. With regard to mechanism, functional status of hepatic OXPHOS 
determined cellular levels of NAD+, a known activator of SIRT1. We provide 
evidence that hepatic OXPHOS dictates SIRT1 activation, an activation which 
controls PGC-1α – HNF4α driven expression of Cyp7a1, the rate limiting enzyme 
in bile acid synthesis. Taken together, these data suggest hepatic OXPHOS 
transcriptionally regulates bile acid composition, driving adipose lipid oxidation 
and energy expenditure thereby protecting from obesity (Fig 4.5).  
  Bile acids are known activators of energy expenditure. Consistent with our 
report, transgenic expression of Cyp7a1 in mice altered bile acid composition, 
which corresponded to increases in energy expenditure and adipose 
thermogenic gene expression (Li et al., 2010c). Bile acids are thought to mediate 
changes in adipose thermogenesis via the G-protein coupled receptor TGR5 
(Broeders et al., 2015; Watanabe et al., 2006). However, others have reported 
alternative pathways by which bile acids regulate whole body energy status 
(Cariou et al., 2006; Fang et al., 2015; Zhang et al., 2006).  Thus, while TGR5-
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induced adipose thermogenesis is a likely mechanism in our model, as well as 
that of Li et al., the precise contribution of this pathway remains unknown. 
Furthermore, recent data indicate that the protective effects of a similar 
thermogenic hepatokine, FGF21, are at least partially independent of adipose 
thermogenesis (Hale et al., 2012; Samms et al., 2015; Veniant et al., 2015). 
Hence, the possibility remains that alternative, parallel pathways contribute the 
protection endowed by hepatic OXPHOS. 
  Our data suggest that the status of hepatic OXPHOS is intimately connected to 
bile acid composition. Obesity and NAFLD are associated with deficient 
OXPHOS capacity (Cortez-Pinto et al., 1999; Perez-Carreras et al., 2003) and 
alterations in bile acid composition (Gustafsson et al., 2005; Lai et al., 2015; Patti 
et al., 2009). However, whether or not these alterations in bile acid composition 
are adaptive, or maladaptive, remains unknown. Interestingly, in our study, chow-
fed mice with impaired hepatic OXPHOS had a bile acid profile similar to that of 
high fat fed animals (Fig 4.S1). Moreover, bile acid composition of mice with 
enhanced hepatic OXPHOS fed a high fat diet was similar to lean controls 
(Cooper Lab, unpublished data). This implies a connection between liver 
metabolic status and alterations in bile acids, in which hepatic OXPHOS serves 
as a metabolic sensor, regulating whole-body energy expenditure. 
  We have provided evidence for a transcriptional regulatory pathway via NAD+ 
and activation of a SIRT1 – PGC-1α – HNF4α axis in promoting CYP7A1 
expression. The regulation of Cyp7a1 is complex, involving multiple overlapping 
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pathways. Though to a lesser extent than HNF4α, the Liver X Receptor (LXR) 
promotes Cyp7a1 expression in liver (Chiang et al., 2001; Peet et al., 1998). 
Interestingly, SIRT1 can directly deacetylate LXR, activating transcription of 
CYP7A1 (Li et al., 2007). We chose to focus on HNF4α in this study as it is 
critically important for bile acid synthetic gene expression (Inoue et al., 2006). 
However, we cannot exclude the possibility of parallel activation of LXR in 
hepatic OXPHOS mediated bile acid synthesis. 
  The regulation of bile acid synthesis by hepatic NAD+ levels has compelling 
implications. In NAFLD, hepatic mitochondria are faced with a greatly increased 
flux of nutrients in the form of free fatty acids (Donnelly et al., 2005). In non-
pathologic state the liver compensates for this by upregulation of fatty acid 
oxidative machinery, thereby coupling nutrient status to metabolic capacity. 
However, overwhelming nutrient flux can create a mismatch between these 
pathways, represented in NAFLD by the observed alterations in redox state and 
increased NADH/NAD+ (Kim et al., 2011). As shown in our study, this mismatch 
may play a role in promoting maladaptive changes in bile acids. In contrast, 
restoration of hepatic OXPHOS restores oxidative capacity, re-coupling fatty acid 
oxidation with nutrient flux and reestablishing an adaptive bile acid composition 
thereby promoting whole-body energetic homeostasis. 
  Bile acid synthesis is a major mechanism for cholesterol disposal within the 
liver. One implication of this may be that activation of the bile acid synthetic 
program in mice with enhanced hepatic OXPHOS would reduce cholesterol 
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levels and favorably affect cardiovascular disease. Of note, transgenic 
expression of CYP7A1 prevented hypercholesterolemia in LDL receptor knockout 
mice and protected against the effects of a atherosclerotic diet (Miyake et al., 
2002; Ratliff et al., 2006). While we did not assess markers of cardiovascular 
health in our model, we would predict enhancing hepatic OXPHOS confer benefit 
in models of atherosclerotic disease. 
  In sum, our results indicate a novel regulation of whole body energy expenditure 
by hepatic OXPHOS. Moreover, these data imply that alterations in hepatic 
OXPHOS in NAFLD may precipitate maladaptive alterations in bile acids, which 
may affect whole body energy status. Together, this represents a critical role for 
liver OXPHOS in regulating metabolic gene expression, a regulation which has 
important therapeutic potential in obesity and diabetes. 
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CHAPTER V: SUMMARY AND FUTURE DIRECTIONS 
 
  Herein we have established a model of enhanced hepatic oxidative 
phosphorylation (OXPHOS) using mice with liver-specific transgenic expression 
of the mitochondrial transcriptional co-activator LRPPRC. Consistent with a role 
for OXPHOS in non-alcoholic fatty liver disease (NAFLD), mice with enhanced 
hepatic OXPHOS were protected from steatosis and liver inflammation. 
Moreover, these mice had improved whole-body insulin sensitivity.  Enhanced 
OXPHOS increased hepatic levels of NAD+ and the ratio of NAD+/NADH, which 
promote fatty acid oxidation in hepatocytes. Interestingly, these mice were also 
protected from the obesogenic effects of long-term high fat feeding, with altered 
bile acid composition, enhanced energy expenditure, and increased oxidative 
gene expression in adipose tissue. Altogether, these results suggest a profound 
role for hepatic OXPHOS in the regulation of whole-body energy expenditure 
through transcriptional regulation of bile acids synthesis. These experiments 
raise several intriguing questions which warrant further discussion. 
 
Is Defective OXPHOS Sufficient to Promote NAFLD? 
  The question remains whether defects in OXPHOS are sufficient to precipitate 
fatty liver disease. In our model, we provide evidence that restoration of hepatic 
OXPHOS mitigates NAFLD in mice, implicates OXPHOS in the pathophysiology 
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of NAFLD. However, it is still unclear whether or not reduced OXPHOS is 
sufficient to promote onset of the disease.  
   Pharmacologic studies support deficient OXPHOS as a possible cause of fatty 
liver. Widely used in both medicine and scientific modelling, the tetracycline class 
of drugs is historically known to cause liver pathology (Dowling and Lepper, 
1964).Tetracylines can inhibit mitochondrial protein synthesis and prevent 
OXPHOS subunit expression (Moullan et al., 2015). Accordingly, this reduces 
fatty acid β-oxidation and induces hepatic steatosis (Freneaux et al., 1988; Labbe 
et al., 1991), supporting OXPHOS-regulated fatty acid metabolism. Induction of 
fatty liver by addition of compounds, however, may have undesirable off-target 
effects. Therefore, ablation of OXPHOS by more specific (i.e. genetic) means will 
yield more valuable understanding of this process. 
  At least one group has reported that OXPHOS deficiency by liver-specific 
deletion of AIF surprisingly protects from high fat feeding (Pospisilik et al., 2007). 
However, these mice had substantial reductions in weight. Concordantly, 
unpublished data from our lab using liver-specific Lrpprc knockout mice indicate 
that ablation of OXPHOS results in weight loss due to yet unclear mechanisms 
(Cooper Lab, unpublished data; discussed in Chapter I). However, the extent to 
which OXPHOS is deficient in human NAFLD is unlikely to reach the severity of 
these models, which may better represent mitochondrial disorders. Thus, the use 
of models such as heterozygous loss of Lrpprc or virally-mediated knockdown of 
the mitochondrial transcriptional machinery may be a more appropriate model 
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human mitochondrial dysfunction. This remains an area ripe for further 
investigation in our lab and elsewhere. 
 
 
  What Inactivates Hepatic OXPHOS in NAFLD? 
  As discussed previously, hepatic OXPHOS is diminished in both patient and 
mouse fatty liver disease (see Chapter I for a detailed review). However, the 
precise mechanism by which this occurs is unknown. Lipids in fatty liver disease 
are primarily derived from serum fatty acids, suggesting that hepatic pathology is 
downstream of increased lipid flux. In support a role for OXPHOS in the onset of 
NAFLD, increased nutrient flux could alter functionality of the electron transport 
chain in several ways. 
  Protein acetylation may alter metabolic function in obesity. Mitochondrial 
proteins, including those involved with OXPHOS, are major targets of lysine 
acetylation (Lundby et al., 2012; Rardin et al., 2013; Still et al., 2013). The 
precise mechanism by which this occurs remains unclear, as, to date, a specific 
mitochondrial acetyl-transferase has not been identified. Nonetheless, these 
reversible modifications can allosterically regulate proteins, inhibiting enzymatic 
functionality (Ahn et al., 2008; Hirschey et al., 2010; Schwer et al., 2006; 
Shimazu et al., 2010). Some have suggested that increased acetyl-CoA resulting 
from substrate oxidation is sufficient to promote protein acetylation (Pougovkina 
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et al., 2014; Wellen et al., 2009), which could connect increased nutrient flux in 
NAFLD to diminished OXPHOS. 
  As discussed in Chapter I, fatty liver is associated with increased mitochondrial 
protein acetylation (Kendrick et al., 2011). Curiously, acetylation status of 
LRPPRC dictates its transcriptional activity (Liu et al., 2014). Experiments in 
Ins2Akita mice reveal hyperacetylation of LRPPRC in liver (Cooper Lab, 
unpublished data). Moreover, TFAM may also be a target of acetylation (Dinardo 
et al., 2003). Taken together, these data could provide a model for diminished 
OXPHOS gene expression in NAFLD. Accordingly, whole-organism loss of the 
mitochondrial deacetylase SIRT3 increases mitochondrial protein acetylation 
resulting in obesity, insulin resistance, and hepatic steatosis in mice (Hirschey et 
al., 2011). However, specific ablation of Sirt3 in liver had no overt metabolic 
effects, despite extensive mitochondrial protein acetylation (Fernandez-Marcos et 
al., 2012). This would argue against acetylation as a causal mechanism, though 
we cannot account for possible compensatory effects from other tissues. Even 
so, mitochondrial protein acetylation remains worth of investigation. 
  The accumulation of reactive oxygen species (ROS) might also interfere with 
functional OXPHOS. Hepatic steatosis is marked by an increase flux of free fatty 
acids into the liver (Donnelly et al., 2005), metabolism of which promotes 
superoxide formation at the electron transport chain (Schonfeld and Wojtczak, 
2007; Seifert et al., 2010). Mitochondrial ROS can inactivate electron transport 
chain activity and cellular ATP synthesis (Hyslop et al., 1988; Zhang et al., 1990). 
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Thus, perhaps fatty acid flux-induced superoxide formation directly inhibits 
electron transport and therefore OXPHOS. Data from mice, however, indicate 
that OXPHOS enzymatic activity is reduced with concomitant reductions in 
mtDNA encoded mRNA transcripts (Garcia-Ruiz et al., 2006; Garcia-Ruiz et al., 
2014). This would suggest regulation of OXPHOS at the transcriptional level and 
not direct enzymatic interference by superoxide.  
  How might oxidative stress regulate mitochondrial transcripts? Increased 
oxidative stress has been shown to deplete mitochondrial RNA (Abramova et al., 
2000; Crawford et al., 1998; Crawford et al., 1997; Shokolenko et al., 2009). This 
is possibly due to direct oxidation of mtDNA by mitochondrial ROS formation 
(Richter et al., 1988) which has been shown to occur in fatty liver (Gao et al., 
2004). Moreover, patients with NAFLD have increased presence of mtDNA 
oxidation and mutation, which could prevent OXPHOS subunit expression 
(Caldwell et al., 1999; Kawahara et al., 2007). 
  Interestingly, the ROS-activated Lon protease (Bota and Davies, 2002; Liu et 
al., 2004) has been shown to degrade the mtDNA stability factor TFAM (see 
Chapter I), thereby regulating mtDNA levels and gene expression (Matsushima 
et al., 2010). Hence, increased superoxide formation could promote Lon-
mediated TFAM degradation, reducing mitochondrial transcripts and diminishing 
OXPHOS. In support of this, protein levels of TFAM are reduced in livers of aged 
rats (Picca et al., 2013, 2014) and ob/ob mice (Holmstrom et al., 2013). However, 
128 
to the best of my knowledge, the effects of NAFLD on TFAM by high-fat feeding 
have not been explored. 
  This model requires reconciliation with two key findings. First, at least one study 
has reported an increase in mtDNA levels in models of fatty liver (Carabelli et al., 
2011). In this study, however, the authors also observed an increase in 
mitochondrial number, which could indicate a reduction in mtDNA copy number 
per mitochondrion. Furthermore, cristae density, the formation of which depends 
on Complex V dimers (Davies et al., 2012), is reduced in NAFLD (Caldwell et al., 
1999; Sanyal et al., 2001), implying a decrease in mitochondrially encoded 
transcripts. Thus, global increases of mtDNA may not reflect per mitochondrion 
biology.  Second, in our model, Lrpprc-mediated transcription of the 
mitochondrial genome persisted, a process which depends on the maintenance 
of mtDNA by TFAM.  Here it is important to note that Lrpprc overexpression 
reduces cellular production of superoxide, which may protect TFAM from 
degradation. Indeed, mice with enhanced hepatic OXPHOS tended to have 
higher levels of mtDNA than controls, in line with a model of ROS-mediated 
TFAM degradation.  
  Thus, hepatic expression of TFAM, and in particular a Lon-resistant mutant, 
may offer similar benefits to the model presented here. This experiment would 
also serve to validate the finding that OXPHOS is protective in fatty liver disease. 
Interestingly, transgenic expression of TFAM was protective in two models of 
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heart failure (Ikeda et al., 2015; Ikeuchi et al., 2005), a disease which also 
exhibits reduced OXPHOS capacity (Rosca et al., 2008).  
 
By What Mechanism Does Enhanced OXPHOS Increase NAD+? 
  The regulation of cellular NAD+ levels by OXPHOS is an intriguing finding. 
While it is intuitive that increased cycling at Complex I would alter the ratio of 
NAD+/NADH, the mechanism by which enhanced OXPHOS promotes total 
cellular [NAD+] is less obvious.  Cellular levels of NAD+ are governed by the 
balance between synthetic and consumptive pathways (Canto et al., 2015). 
Synthesis can occur de novo from tryptophan, via the Preiss-Handler pathway 
from precursor nicotinic acid, or by salvage of the breakdown product 
nicotinamide. On the other hand, breakdown of NAD+ occurs via its use as a co-
factor for several enzymes: Sirtuins, poly(ADP-ribose) polymerases, and cyclic 
ADP-ribose synthases (e.g. CD38). In light of the data presented here, these 
pathways warrant further exploration. 
  While NAD+ synthetic enzyme expression was unchanged in our study, this 
does not preclude increased synthesis as a potential mechanism for increased 
[NAD+]. Synthesis of NAD+ is primarily regulated by the rate limiting the enzyme 
nicotinic acid phosphoribosyltransferase (NAMPT) (Revollo et al., 2004). 
Ribosylation of NAD+ precursor molecules requires ATP, either as a direct co-
factor, or in the synthesis of phosphoribosyl pyrophosphate. Since levels of 
LRPPRC dictate ATP synthesis (Liu et al., 2011; Mourier et al., 2014), this may 
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be a mechanism by which hepatic OXPHOS regulates cellular NAD+ levels. 
Suggestive of its function as a major consumer of energy, inhibition of NAMPT 
elevates cellular ATP levels (Pittelli et al., 2010). Additionally, in vitro studies 
reveal that increasing levels of ATP accelerate NAMPT enzymatic activity 
(Burgos and Schramm, 2008).Thus, perhaps augmented OXPHOS is coupled to 
NAD+ synthesis via increases in ATP. The relative contribution of this pathway in 
our system is yet unexplored. 
  Reduced consumption could also influence NAD+ levels in OXPHOS-replete 
hepatocytes. Poly(ADP-ribose) polymerase activity represents a major NAD+ 
consumptive mechanism  via ADP-ribosylation of proteins. In support of this, 
knockout of either PARP1 or PARP2 increased tissue NAD+ levels in mice (Bai 
et al., 2011a; Bai et al., 2011b). Importantly, increased in NAD+ in PARP-null 
mice was also protective against high fat feeding. Multiple studies indicate PARP 
localize to the mitochondrion (Du et al., 2003; Rossi et al., 2009) and can be 
activated by oxidative stress (Du et al., 2003; Kiningham et al., 1999). 
Interestingly deletion of PARP1 or PARP2 also increased levels of SIRT1 protein, 
which indicates a reciprocal regulation of these pathways (Bai et al., 2011a; Bai 
et al., 2011b). The SIRT1 increases observed in LRPPRC transgenic livers may 
indicate a similar effect. Thus, evaluation of PARP activation may be of value in 
our model of enhanced OXPHOS with coordinate reductions in ROS formation. 
Similarly, knockout of CD38 increased tissue [NAD+] and protected from high fat 
feeding in two mouse models (Barbosa et al., 2007; Chiang et al., 2015). Loss of 
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CD38 was also associated with increased energy expenditure, however, 
alterations in adipocyte gene expression were not evaluated. Nonetheless, CD38 
activation may be yet another mechanism for NAD+ modulation in LRPPRC 
transgenic mice. 
 
How Does Hepatic OXPHOS Regulate Inflammation? 
  Mice with enhanced hepatic OXPHOS had a significant reduction in 
inflammation following high fat feeding. This is of substantial interest, as the 
progression to steatohepatitis and cirrhosis is thought to primarily derive from 
inflammation. Kupffer cell activation is an essential feature for the progression of 
fatty liver disease (Huang et al., 2010; Lanthier et al., 2011; Negrin et al., 2014; 
Tosello-Trampont et al., 2012; Wan et al., 2014). In our model, we saw a 
significant reduction in a panel of inflammatory markers, including CCL2, a 
macrophage activating chemokine. This could imply a reduction in Kupffer cell 
activation within livers with enhanced hepatic OXPHOS. 
  Since our model specifically alters OXPHOS within hepatocytes, reduced 
inflammation is likely the result of a communication between hepatocytes and 
immune cells. Evidence suggests fatty acid accumulation activates the innate 
immune response (Miura et al., 2013; Shi et al., 2006). In NAFLD, activation of 
hepatocyte toll-like receptor 4 (TLR-4) promotes local cytokine response and 
inflammation (Li et al., 2011a) alongside stimulating fibrosis (Seki et al., 2007). 
Moreover, in response to fatty acids, the liver secretes fetuin-A, which can in turn 
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activate TLR4 in an endocrine manner (Dasgupta et al., 2010; Hennige et al., 
2008; Pal et al., 2012). Interestingly, these mechanisms converge at NF-κB, 
which can also be activated by reactive oxygen species (Kauppinen et al., 2013). 
Thus, by means of reduced fatty acid accumulation, reduced superoxide 
formation, or both, enhanced hepatic OXPHOS could attenuate inflammation. 
Whether or not signaling by NF- κB, TLR-4, or Fetuin-A is less prominent in 
LRPPRC transgenic livers is not yet known. In addition, emerging studies 
indicate that mitochondrial dysfunction, in the form of mitochondrial DNA 
depletion, may potentiate the innate immune system (West et al., 2015). This 
could provide a model of direct regulation of hepatocyte immune response by 
mitochondrial dysfunction, an intriguing proposition in the pathophysiology of 
NASH. 
 
Do Parallel Pathways Mediate the Effects of Hepatic OXPHOS? 
  Here we have presented evidence for the regulation of transcription of bile acid 
synthetic genes via a SIRT1 – PGC-1α – HNF4α axis via OXPHOS-mediated 
increases in NAD+ levels. However, it is likely that an abundance of NAD+ 
affects a broad array of transcriptional pathways, regulation of which could 
operate in cooperation with or in addition to those described here. 
  Several nuclear receptors with overlapping activity regulate the expression of 
bile acid synthesis (Chiang, 2009). In particular, the nuclear receptor LXR is a 
potent regulator of is a potent activator of Cyp7a1 expression (Chiang et al., 
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2001; Gupta et al., 2002; Lehmann et al., 1997). Moreover, SIRT1 directly 
deacetylates LXR, simulating transcriptional activity and subsequent ubiquitin-
mediated degradation (Li et al., 2007). Thus, activation of bile acid synthesis in 
enhanced hepatic OXPHOS could be mediated in parallel by effects on LXR. 
Interestingly, we did not observe decreases in LXR protein levels in liver-specific 
LRPPRC transgenic mice, however, we cannot account for compensatory effects 
of chronic SIRT1 activation in our constitutively activated model. 
  The acetylation status of PGC-1α in liver could have important metabolic 
consequences. Activation of PGC-1α enhances cooperation with HNF4α to 
promote induction of gluconeogenesis in the fasting state (Rhee et al., 2006; 
Rodgers et al., 2005; Yoon et al., 2001). Thus, it is possible the positive effects 
by hepatic OXPHOS on steatosis are confounded by fasting hyperglycemia. 
Indeed, expression of LRPPRC increases expression of gluconeogenic enzymes 
Pepck and G6pase. Despite this, we did not observe significant alterations in 
fasting glucose levels between transgenic and control animals. Previous work 
suggests a nuclear role for LRPPRC in the regulation of PGC-1α target genes 
(Cooper et al., 2006). In this study, our data suggest an alternate, and perhaps 
complimentary, role in the regulation of gluconeogenesis; that is, enhanced 
levels of NAD+ result in deacetylation of PGC-1α and cooperation with HNF4α. 
Subcellular localization studies indicate that LRPPRC is predominantly 
mitochondrial. Even so, the relative contribution by each of these pathways is 
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unknown. Careful dissection of these pathways could enhance our understanding 
of the precise role of LRPPRC in hepatic metabolism. 
 
Is Protection from Obesity Dependent on Adipose Tissue Thermogenesis and 
TGR5? 
  Mice with enhanced hepatic OXPHOS have altered bile acid synthesis 
alongside increased energy expenditure and an oxidative phenotype in adipose 
tissue. Our data are consistent with previous mouse models of increased Cyp7a1 
expression, which suggest bile acid synthesis in liver promotes energy 
expenditure (Li et al., 2010c). Bile acids are known to activate adipose tissue 
thermogenesis via the G-protein coupled receptor TGR5 (Broeders et al., 2015; 
Watanabe et al., 2006), however, the dependence of the observed phenotypes 
on adipose tissue and TGR5 remain unknown.  
  Mouse TGR5 is expressed in a multitude of tissues. Indeed, reports suggest the 
receptor plays a role in regulating GLP-1 secretion (Zheng et al., 2015), 
glycogenolysis (Potthoff et al., 2013), gall bladder filling and gallstone formation 
(Li et al., 2011b; Vassileva et al., 2006), vascular healthy (Kida et al., 2013), 
macrophage activation (Perino et al., 2014), neuroinflammation (McMillin et al., 
2015), and bile induced itch (Alemi et al., 2013; Lieu et al., 2014). Thus, the 
tissue specific effects of bile acid induction are difficult to tease apart. In our 
model, and that of Li et al., alterations in adipose tissue gene expenditure 
represent the most likely pathway for beneficial metabolic effects. Nevertheless, 
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further analysis with adipose-specific deletion of TGR5 or UCP1-/- mice would 
provide critical understanding of bile acid induced energy expenditure . 
  Bile acids activate several receptors in addition to TGR5. Specifically, activation 
of FXR has been shown to have favorable effects on metabolism (Cariou et al., 
2006; Fang et al., 2015; Zhang et al., 2006). While we did not observe overt 
alterations in FXR target genes in mice with enhanced hepatic OXPHOS, 
activation of FXR cannot be ruled out. Of particular interest, intestinal activation 
of FXR leads to FGF15-mediated browning of adipose tissue (Fang et al., 2015), 
which could present an alternative mechanism for the adipocyte phenotype seen 
here. Exploration of bile acid receptors and their role in mediating these effects 
would help to guide therapies, as these are both targets ripe for clinical 
development. 
 
Does Enhanced OXPHOS Interact With Additional Pathophysiology? 
  Mitochondrial dysfunction and reduced OXPHOS are present in a multitude of 
pathologies (Wallace, 2005, 2013). Moreover, enhanced cellular NAD+ and 
SIRT1 activation have shown to be of benefit in numerous disease processes 
(Canto et al., 2015). Thus, our model of enhanced OXPHOS with corresponding 
increases in NAD+ may have favorable effects in other disease, both witin the 
liver and beyond. I will conclude this discussion by highlighting a few areas in 
which enhanced OXPHOS may support healthfulness. 
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Alcoholic Liver Disease 
  Fatty liver disease can derive from numerous toxic and metabolic insults. 
Alcoholic liver disease is a major cause of fatty liver, hepatitis, and cirrhosis with 
similarities to NAFLD (O'Shea et al., 2010). Alcoholic liver disease presumably 
initiates from the effects of ethanol metabolism via alcohol dehydrogenase and 
subsequent metabolism by aldehyde dehydrogenase, both of which require 
oxidized NAD+ as a cofactor. Excessive alcohol metabolism reduces cellular 
NAD+, requiring oxidation through both the electron transport chain as well as 
alternative pathways, namely CYP2E1, which can result in oxidative stress (Lu 
and Cederbaum, 2008). As expected, NAD+/NADH is reduced in alcoholic 
steatosis (Zhou et al., 2014). Chronic alcoholism also reduces SIRT1 protein 
levels (Lieber et al., 2008). Additionally, numerous reports indicate mitochondrial 
dysfunction in chronic alcoholism, including increased ROS formation (Bailey et 
al., 1999), mtDNA damage (Cahill et al., 1999; Cahill et al., 1997), and reductions 
in OXPHOS capacity (Garcia-Ruiz et al., 1994). These data indicate that 
mitochondrial dysfunction and the inability to modulate NAD+/NADH may be a 
driving force in alcoholic liver damage.    
  Interestingly, all-trans retinoic acid, which promotes OXPHOS in cultured 
adipocytes (Tourniaire et al., 2015) also rescues mitochondrial function and liver 
health in ethanol feeding (Nair et al., 2015). LRPPRC-driven OXPHOS augments 
cellular [NAD+] with concordant reductions in ROS formation. Moreover, SIRT1 
activation and total protein levels were increased. Thus, enhanced hepatic 
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OXPHOS may mitigate the detrimental effects of chronic alcoholism via NAD+-
driven ethanol metabolism, reduced oxidative stress, and increased SIRT1 
activation. 
 
Cancer 
  Altered metabolism has long been observed as a hallmark of malignancy. 
Originally postulated by Otto Warburg to be an essential progression to 
tumorigenesis, downregulation of OXPHOS is present in many tumor cells 
(Warburg, 1956). Though this alteration may not be due to dysfunctional 
mitochondria (Fantin et al., 2006), proliferating tumors have altered redox states 
with reductions in NAD+/NADH (Schwartz et al., 1974), thought to be necessary 
fuel for anabolic pathways (Vander Heiden et al., 2009).  
  In light of this, one study explored the role of redox balance, and by proxy, 
mitochondrial function in an aggressive breast cancer cell line. Santidrian et al. 
restored cellular NAD+/NADH using the yeast NADH dehydrogenase Ndi1 
(Santidrian et al., 2013). Interestingly, enhanced complex I activity prevented 
tumor growth and metastasis in a mouse transplant model, while knockdown of 
endogenous NADH dehydrogenase caused a reciprocal effect, promoting tumor 
growth. While only a single report, these results represent proof of principle that 
modulation of NAD+/NADH (perhaps via enhanced OXPHOS) may have benefit 
in tumor treatment.  
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  I should acknowledge, however, that disruption of OXPHOS is also considered 
a potential therapy in many tumors (Pollak, 2013). Additionally, two groups 
recently reported the primary function of the respiratory chain in proliferating cells 
is to fuel aspartate synthesis in proliferating cells (Birsoy et al., 2015; Sullivan et 
al., 2015). Thus, enhanced hepatic OXPHOS may enhance cellular proliferation, 
rather than inhibit it. Indeed, the relative importance of altered metabolism and 
diminished OXPHOS in cancer remains ambiguous.  
 
Aging 
  Mitochondrial dysfunction is a striking feature of aging. (Muller-Hocker, 1989; 
Petersen et al., 2003; Short et al., 2005; Trounce et al., 1989). As reviewed in 
Chapter I, the mitochondrial and oxidative stress theory of aging remains a 
prominent hypothesis for the aging process. Consistent with this hypothesis, 
markers of oxidative stress accumulate with age (Andriollo-Sanchez et al., 2005). 
Since mitochondria are a primary source of superoxide, one plausible 
explanation is that mitochondrial ROS drive the aging process. Supporting this 
hypothesis, expression of a mitochondrial targeted catalase prevents aging and 
its associated insulin resistance in mice (Lee et al., 2010; Schriner et al., 2005). 
  An additional hypothesis of aging originates from caloric restriction. 
Experiments demonstrating caloric restriction begets longevity have been 
performed in almost every level of organism, from single cells to mammals 
(Guarente and Picard, 2005). Interestingly, it was discovered that caloric 
139 
restriction promotes longevity via activation of the NAD+ dependent ortholog of 
SIRT 1 – yeast SIR2 (Imai et al., 2000; Lin, 2000). Follow-up studies suggest that 
SIRT1 activation may counteract the aging process in animals (Mitchell et al., 
2014).This implies that activation of SIRT1 by NAD+ may offer equivalent 
benefits. 
  Our model seemingly converges on these two pathways. By overexpression of 
LRPPRC, we have enhanced OXPHOS, resulting in simultaneously increased 
NAD+ levels and lower ROS formation within mitochondria. It stands to reason 
that these effects might convey benefit to an entire organism via extension of life. 
Further experiments with whole-body expression of LRPPRC would help to 
answer this question. 
 
Concluding Remarks 
In summary, we have developed a model of enhanced hepatic OXPHOS by 
specifically overexpressing LRPPRC in liver. Enhanced OXPHOS in liver 
protected against the formation of fatty liver disease and promoted whole-body 
insulin sensitivity. Moreover, hepatic OXPHOS induced a marked increase in 
NAD+, which promotes complete oxidation of fatty acids. Intriguingly, hepatic 
OXPHOS altered bile acid composition, increased adipocyte oxidative gene 
expression, and augmented energy expenditure, thereby mitigating the effects 
high fat feeding. Livers from mice with enhanced hepatic OXPHOS had 
increased SIRT1 activation, which activates PGC-1α and increases expression of 
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CYP7A1, the rate limiting bile synthetic enzyme. These data suggest that the 
status of hepatic OXPHOS regulates whole-body energy balance via a NAD+ – 
SIRT1 – PGC1-α– CYP7A1 axis, culminating in adipose thermogenesis and 
protection from obesity. 
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